var title_f31_19_32048="Kyphosis PI";
var content_f31_19_32048=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F83274&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F83274&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 558px\">",
"   <div class=\"ttl\">",
"    Kyphosis caused by osteoporosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 538px; height: 424px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Kyphosis is the medical term for when the upper part of the spine curves forward, causing the back to look rounded or hunched. The most common cause of kyphosis in adults is osteoporosis, a condition that weakens bones. This picture shows a young woman on the left who does not have kyphosis. The woman in the middle is starting to show signs of it. The oldest woman on the right has kyphosis caused by osteoporosis. Besides making the spine curve, kyphosis also causes the belly to bulge.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_19_32048=[""].join("\n");
var outline_f31_19_32048=null;
var title_f31_19_32049="Uvulitis";
var content_f31_19_32049=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F67939&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F67939&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 523px\">",
"   <div class=\"ttl\">",
"    Uvular edema and erythema",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 503px; height: 180px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Inflammation of the uvula in association with tonsillar and posterior pharyngeal involvement.",
"    <br/>",
"    (A) Redness and vascularity of the tonsillar pillars and uvula are mild to moderate. The uvula is moderately swollen.",
"    <br/>",
"    (B) Redness is diffuse and intense.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Bickley LS, Szilagyi PG. Bates' guide to physical examination and history taking (8th ed.). Philadelphia: Lippincott Williams &amp; Wilkins, 2003. Copyright &copy; 2003 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_19_32049=[""].join("\n");
var outline_f31_19_32049=null;
var title_f31_19_32050="Indium In-111 pentetreotide: Drug information";
var content_f31_19_32050=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Indium In-111 pentetreotide: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?15/33/15891?source=see_link\">",
"    see \"Indium In-111 pentetreotide: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F14877563\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      OctreoScan&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F13181732\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Radiopharmaceutical",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F13182020\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Planar imaging:",
"     </b>",
"     I.V.: 3 mCi (111 MBq)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Single photon emission computed tomograph (SPECT) imaging:",
"     </b>",
"     I.V.: 6 mCi (222 MBq)",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F13182019\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     I.V.: 0.14 mCi/kg (5 MBq/kg)",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15897863\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling; use with caution.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15897864\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F14877564\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Kit,  [preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     OctreoScan&reg;:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Injection, powder for reconstitution: Pentetreotide 10 mcg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Injection, solution: Indium In-111 chloride 111 MBq (3.0 mCi) per 1 mL (1.1 mL)",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F13191456\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Patient should be well-hydrated before and after administration. Laxatives should be used before and for 48 hours after receiving indium In-111 pentetreotide.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F13181733\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Scintigraphic localization of primary and metastatic neuroendocrine tumors with somatostatin receptors",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F13255252\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Other safety concerns:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Radiopharmaceutical: Use appropriate precaution for handling, disposal, and minimizing exposure to patients and healthcare personnel. Use under supervision of experienced personnel. Should be stored in original lead container or adequate radiation shield.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F13181803\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Radiopharmaceutical: Use appropriate precautions for handling, disposal, and minimizing exposure to patients and healthcare personnel. Use under supervision of individuals who have received training in the handling of radioactive materials and who are authorized by the applicable regulatory authority.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Glucose regulation: May cause severe hypoglycemia in patients with insulinomas; use with caution. Administer glucose before and during indium In-111 pentetreotide administration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Octreotide acetate: Sensitivity of scintigraphy may be reduced with concurrent octreotide; consider temporarily withdrawing octreotide prior to scintigraphy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F13181958\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13181959\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal studies have not been conducted. There are no adequate and well-controlled studies in pregnant women. Radiopharmaceuticals have the potential to cause fetal harm. Use during pregnancy only if clearly needed.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F13181969\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F13182003\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     In one patient report, only 0.025% of the administered dose was excreted in breast milk, which would have resulted in an infant dose of 82 mrem (0.82 mSv) if breast-feeding had not been interrupted. This amount is so low that interruption of breast-feeding is not necessary; however, the radiation exposure to the infant from the mother while being held in close contact may be sufficiently high that interruption of breast-feeding may be recommended in order to limit the time of close contact (Rubow, 2000).",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Balon HR, Goldsmith SJ, Siegel BA, et al, \"Society of Nucelar Medicine Procedure Guideline for Somatostatin Receptor Scintigraphy with IN-111 Pentetreotide,\" J Nucl Med, 2001, 42(7):1134-8. Available at file://interactive.snm.org/docs/pg_ch27_0403.pdf. Last accessed April 27, 2010.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/19/32050/abstract-text/11438641/pubmed\" id=\"11438641\" target=\"_blank\">",
"        11438641",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rubow SM and Ellman A, \"Indium-111 Scintigraphy and Breastfeeding,\"",
"      <i>",
"       Eur J Nucl Med",
"      </i>",
"      , 2000, 27(8):1057.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16797 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-93.125.6.160-7DBF348CA4-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_19_32050=[""].join("\n");
var outline_f31_19_32050=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14877563\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13181732\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13182020\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13182019\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15897863\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15897864\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14877564\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13191456\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13181733\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13255252\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13181803\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13181958\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13181959\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13181969\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13182003\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/16797\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/16797|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?15/33/15891?source=related_link\">",
"      Indium In-111 pentetreotide: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_19_32051="Methyl aminolevulinate: Patient drug information";
var content_f31_19_32051=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Methyl aminolevulinate: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/7/35955?source=see_link\">",
"     see \"Methyl aminolevulinate: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F12607838\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Metvixia&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F12607839\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Metvix&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F12624541\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692074",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat skin cancer.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F12624540\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3378081",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to methyl aminolevulinate or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2749554",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to peanuts, talk with the doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3378086",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to almond oil, talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F12624545\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697794",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may get sunburned more easily. Avoid sun, sunlamps, bright indoor lights, and tanning beds. Wear clothing and eyewear that protects you from the sun. Sunscreens will not protect you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F12624546\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698344",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697945",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in color of skin where drug is used.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698359",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sunburn.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F12624548\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F12624543\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696053",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug is used with light therapy.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696363",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Your doctor will put on the skin.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F12624544\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696446",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Call your doctor to find out what to do.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F12624549\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699596",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug will be given to you in a hospital or doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F12624550\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16482 Version 17.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-61.234.146.186-67DC1C7482-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_19_32051=[""].join("\n");
var outline_f31_19_32051=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12607838\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12607839\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12624541\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12624540\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12624545\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12624546\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12624548\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12624543\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12624544\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12624549\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12624550\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?35/7/35955?source=related_link\">",
"      Methyl aminolevulinate: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_19_32052="Penile condyloma acuminatum in a child";
var content_f31_19_32052=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F83497&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F83497&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Condyloma acuminatum",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Soft brown papules are present on the penis of this child.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_19_32052=[""].join("\n");
var outline_f31_19_32052=null;
var title_f31_19_32053="Lymphangioleiomyomatosis CT I";
var content_f31_19_32053=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F69954%7EPULM%2F78552&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F69954%7EPULM%2F78552&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Lymphangioleiomyomatosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 249px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Lymphangioleiomyomatosis in a 42-year-old woman. Multiple small cysts permeate the entire lung parenchyma.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Advanced lymphangioleiomyomatosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 325px; height: 187px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Advanced lymphangioleiomyomatosis characterized by severe destruction of the lung parenchyma with replacement by cysts.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_19_32053=[""].join("\n");
var outline_f31_19_32053=null;
var title_f31_19_32054="ECG_2 Polymorphic VT in ischemia";
var content_f31_19_32054=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F67322&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F67322&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 561px\">",
"   <div class=\"ttl\">",
"    ECG_2 showing polymorphic ventricular tachycardia in ischemia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 541px; height: 212px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Continuous rhythm strip showing an episode of very rapid polymorphic ventricular tachycardia which is often referred to as ventricular flutter. The QT interval is normal and the QRS complex morphology is highly variable. The patient had an underlying sinus tachycardia, suggesting increased sympathetic activity secondary to an ischemic event.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_19_32054=[""].join("\n");
var outline_f31_19_32054=null;
var title_f31_19_32055="Pramipexole: Drug information";
var content_f31_19_32055=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Pramipexole: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?35/4/35908?source=see_link\">",
"    see \"Pramipexole: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block spa drugH1Div\" id=\"F15054175\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Special Alerts",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Ongoing Safety Review Regarding Potential Risk of Heart Failure",
"     </span>",
"     <span class=\"collapsible-date\">",
"      September 2012",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       The U.S. Food and Drug Administration (FDA) is informing healthcare practitioners of an ongoing safety review of pramipexole. The safety review was prompted by the results of various studies suggesting a potential risk of heart failure (HF) associated with use.",
"      </p>",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       The agency evaluated pooled analysis of randomized, placebo-controlled phase 2 and 3 clinical trials which showed an increased incidence of newly diagnosed HF in patients receiving pramipexole (n=12 /4157; 0.28%) compared to patients receiving placebo (n=4/2820; 0.14%); this difference in incidence is",
"       <b>",
"        not",
"       </b>",
"       statistically significant. The FDA also reviewed results of two epidemiologic studies which suggested an increased incidence in HF. The first epidemiologic study, a case-control study in a United Kingdom cohort of patients receiving anti-Parkinson agents (eg, dopamine agonists), revealed a statistically-significant increased risk for HF in patients exposed to any dopamine agonist compared to no exposure (RR: 1.58; 95% CI: 1.26-1.96). Of the dopamine agonist agents, pramipexole use was associated with a statistically-significant risk of HF in patients exposed to pramipexole versus no exposure (RR: 1.86; 95% CI: 1.21-2.85). In the second epidemiologic study, a case-control study in a cohort of Parkinson&rsquo;s disease patients newly initiated on  a dopamine agonist or levodopa, found that among the individual non-ergot dopamine agonists studied, only current use of pramipexole was associated with an increased risk of HF compared to levodopa use (OR: 1.61; 95% CI: 1.09-2.38). This increased risk occurred in the first 3 months of treatment (OR: 3.06; 95% CI: 1.74-5.39) and in patients &ge;80 years (OR: 3.30; 95% CI: 1.62-7.13). Of note, the increased risk was not significant with pramipexole use &gt;3 months.",
"      </p>",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       The FDA has not concluded that pramipexole increases the risk of HF. Due to study limitations and the potential for confounders, the FDA is continuing its review. The FDA is reminding patients they should not discontinue pramipexole without consulting a healthcare professional. Practitioners should continue to follow recommendations in the pramipexole prescribing information and counsel patients to seek medical attention if any signs/symptoms of HF occur during use.",
"      </p>",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       Additional information may be found at",
"       <a href=\"file://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm320054.htm?source=govdelivery\" target=\"_blank\">",
"        file://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm320054.htm?source=govdelivery",
"       </a>",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F212309\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Mirapex&reg;;",
"     </li>",
"     <li>",
"      Mirapex&reg; ER&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F212310\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Pramipexole&reg;;",
"     </li>",
"     <li>",
"      Ava-Pramipexole;",
"     </li>",
"     <li>",
"      CO Pramipexole;",
"     </li>",
"     <li>",
"      Mirapex&reg;;",
"     </li>",
"     <li>",
"      PMS-Pramipexole;",
"     </li>",
"     <li>",
"      Sandoz-Pramipexole;",
"     </li>",
"     <li>",
"      Teva-Pramipexole",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F212335\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Anti-Parkinson's Agent, Dopamine Agonist",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F212313\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     <b>",
"      Note:",
"     </b>",
"     Retitration of dose should be considered for any significant interruption in therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Parkinson's disease:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Immediate release formulation:",
"     </i>",
"     Initial: 0.125 mg 3 times daily, increase gradually every 5-7 days; maintenance (usual): 0.5-1.5 mg 3 times daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Discontinuation of therapy:  Reduce dose by 0.75 mg daily until daily dose is equivalent to 0.75 mg once daily, then reduce by 0.375 mg daily thereafter",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Extended release formulation:",
"     </i>",
"     Initial: 0.375 mg once daily; increase gradually to 0.75 mg once daily. If necessary, may increase by 0.75 mg per dose not more frequently than every 5-7 days; maximum recommended dose 4.5 mg once daily.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Discontinuation of therapy: Taper gradually over a period of 1 week.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Converting from immediate release to extended release:",
"     </i>",
"     May initiate extended release preparation the morning after the last immediate release evening tablet is taken. The total daily dose should remain the same.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Restless legs syndrome:",
"     </b>",
"     Oral:",
"     <i>",
"      Immediate release formulation:",
"     </i>",
"     Initial: 0.125 mg once daily 2-3 hours before bedtime. Dose may be doubled every 4-7 days up to 0.5 mg once daily. Maximum: 0.5 mg once daily  (manufacturer&rsquo;s recommendation).",
"     <b>",
"      Note:",
"     </b>",
"     Most patients require &lt;0.5 mg daily, but higher doses have been used (2 mg daily). If augmentation occurs, dose earlier in the day.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Discontinuation of therapy:  No gradual dose reduction recommended in manufacturer&rsquo;s labeling; however, worsening of symptoms may occur with abrupt discontinuation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Depression (unlabeled use):",
"     </b>",
"     Oral:",
"     <i>",
"      Immediate release formulation:",
"     </i>",
"     Initial: 0.25-0.375 mg daily given in 2-3 divided doses with a gradual titration; mean dose: 1.6-1.7 mg daily (Aiken, 2007; Goldberg, 2004)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Fibromyalgia (unlabeled use):",
"     </b>",
"     Oral:",
"     <i>",
"      Immediate release formulation:",
"     </i>",
"     Initial: 0.25 mg once daily at bedtime; may be increased weekly by 0.25 mg/day increments up to 4.5 mg daily (Holman, 2005)",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F212314\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F212315\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Parkinson's disease:",
"     </b>",
"     <i>",
"      Immediate release formulation:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &gt;50 mL/minute: No dosage adjustment necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     30-50 mL/minute: Initial: 0.125 mg twice daily (maximum: 0.75 mg 3 times daily)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     15-29 mL/minute: 0.125 mg once daily (maximum: 1.5 mg once daily)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;15 mL/minute: No dosage adjustment provided in manufacturer&rsquo;s labeling (has not been studied); use not recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     ESRD requiring hemodialysis: No dosage adjustment provided in manufacturer&rsquo;s labeling (has not been studied); use not recommended; a negligible amount of pramipexole is removed by dialysis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Parkinson's disease:",
"     </b>",
"     <i>",
"      Extended release formulation:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &gt;50 mL/minute: No dosage adjustment necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     30-50 mL/minute: Initial: 0.375 mg every other day; may increase to 0.375 mg once daily no sooner than 1 week after initiation. If necessary, may increase by 0.375 mg per dose not more frequently than every 7 days; maximum recommended dose: 2.25 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute: No dosage adjustment provided in manufacturer&rsquo;s labeling (has not been studied); use not recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     ESRD requiring hemodialysis: No dosage adjustment provided in manufacturer&rsquo;s labeling (has not been studied); use not recommended; a negligible amount of pramipexole is removed by dialysis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Restless legs syndrome:",
"     </b>",
"     <i>",
"      Immediate release formulation:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &gt;60 mL/minute: No dosage adjustment necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     20-60 mL/minute: No dosage adjustment necessary; however, duration between titration should be increased to 14 days.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;20 mL/minute: No dosage adjustment provided in manufacturer&rsquo;s labeling (has not been studied).",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15028352\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dosage adjustment in hepatic impairment:  Immediate release and extended release: No dosage adjustment provided in manufacturer&rsquo;s labeling (has not been studied); however, no adjustment expected since undergoes minimal hepatic metabolism.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F212288\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as dihydrochloride monohydrate: 0.125 mg, 0.25 mg, 0.5 mg, 0.75 mg, 1 mg, 1.5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mirapex&reg;: 0.125 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mirapex&reg;: 0.25 mg, 0.5 mg [scored]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mirapex&reg;: 0.75 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mirapex&reg;: 1 mg, 1.5 mg [scored]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, extended release, oral, as dihydrochloride monohydrate:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mirapex&reg; ER&reg;: 0.375 mg, 0.75 mg, 1.5 mg, 2.25 mg, 3 mg, 3.75 mg, 4.5 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F212275\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Excludes extended release tablet",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F212291\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Doses should be titrated gradually in all patients to avoid the onset of intolerable side effects. The dosage should be increased to achieve a maximum therapeutic effect, balanced against the side effects of dyskinesia, hallucinations, somnolence, and dry mouth. May be administered with or without food; may be administered with food to decrease nausea. Extended release tablets should be swallowed whole and not chewed, crushed, or divided.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F212289\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Immediate release: Treatment of the signs and symptoms of idiopathic Parkinson's disease; treatment of moderate-to-severe primary Restless Legs Syndrome (RLS)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Extended release: Treatment of the signs and symptoms of idiopathic Parkinson&rsquo;s disease",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F212331\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of depression in bipolar disorder; treatment of fibromyalgia",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F212341\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Mirapex&reg; may be confused with Hiprex&reg;, Mifeprex&reg;, MiraLax&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F212333\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Parkinson&rsquo;s disease:",
"     </b>",
"     Actual frequency may be dependent on dose and/or formulation:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Orthostatic hypotension (dose related; &le;53%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Somnolence (dose related; 9% to 36%), extrapyramidal syndrome (28%), insomnia (4% to 27%), dizziness (2% to 26%), hallucinations (5% to 17%), abnormal dreams (11%), headache (4% to 7%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea (dose related; 11% to 28%), constipation (dose related; 6% to 14%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Dyskinesia (17% to 47%), weakness (1% to 14%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Accidental injury (17%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Edema (2% to 8%), chest pain (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Confusion (4% to 10%), dystonia (2% to 8%), fatigue (6%), amnesia (dose related; 4% to 6%), sudden onset of sleep (3% to 6%), vertigo (2% to 4%), hypesthesia (3%), abnormal thinking (2% to 3%), akathisia (2% to 3%), malaise (2% to 3%), paranoia (2%), sleep disorder (1% to 3%), depression (&le;2%), delusions (1%), fever (1%), myoclonus (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Libido decreased (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Xerostomia (4% to 7%), anorexia (1% to 5%), vomiting (4%), abdominal discomfort/pain (1% to 4%), dyspepsia (3%), appetite increased (2% to 3%), dysphagia (2%), weight loss (2%), salivary hypersecretion (&le;2%), diarrhea (1% to 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Urinary frequency (6%), urinary tract infection (4%), impotence (2%), urinary incontinence (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Gait abnormalities (7%), hypertonia (7%), muscle spasm (3% to 5%), falls (4%), arthritis (3%), tremor (3%), back pain (2% to 3%), bursitis (2%), muscle twitching (2%), balance abnormalities (&le;2%), CPK increased (1%), myasthenia (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Accommodation abnormalities (4%), vision abnormalities (3%), diplopia (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Dyspnea (4%), cough (3%), rhinitis (3%), pneumonia (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Postmarketing and/or case reports (Limited to important or life-threatening): Blackouts, heart failure, impulsive/compulsive behaviors (eg, binge eating, hypersexuality, pathological gambling, shopping), libido increased, pruritus, rhabdomyolysis, SIADH, syncope",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Restless legs syndrome:",
"     </b>",
"     Actual frequency may be dependent on dose:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache (16%), insomnia (9% to 13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea (11% to 27%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Fatigue (3% to 9%), abnormal dreams (1% to 8%), somnolence (6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea (1% to 7%), constipation (4%), xerostomia (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Limb pain (3% to 7%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Nasal congestion (&le;6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Influenza (1% to 7%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Postmarketing and/or case reports (Limited to important or life-threatening): Augmentation (~20% but similar to placebo), blackouts, hallucinations, hypotension, impulsive/compulsive behaviors (eg, binge eating, hypersexuality, pathological gambling, shopping), libido changes, pruritus, rebound, tolerance, syncope",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F212294\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no contraindications listed in the manufacturer's labeling.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F212279\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Dyskinesias: May cause or exacerbate dyskinesias. Use with caution in patients with pre-existing dyskinesias.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hallucinations: May cause hallucinations, particularly in older patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Impulse control disorders: Dopamine agonists used for Parkinson&rsquo;s disease or restless legs syndrome have been associated with compulsive behaviors and/or loss of impulse control, which has manifested as pathological gambling, libido increases (hypersexuality), and/or binge eating. Causality has not been established, and controversy exists as to whether this phenomenon is related to the underlying disease, prior behaviors/addictions and/or drug therapy. Dose reduction or discontinuation of therapy has been reported to reverse these behaviors in some, but not all cases.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Melanoma: Risk for melanoma development is increased in Parkinson&rsquo;s disease patients; drug causation or factors contributing to risk have not been established. Patients should be monitored closely and periodic skin examinations should be performed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Orthostatic hypotension: May cause orthostatic hypotension; Parkinson's disease patients appear to have an impaired capacity to respond to a postural challenge. Use with caution in patients at risk of hypotension (such as those receiving antihypertensive drugs) or where transient hypotensive episodes would be poorly tolerated (cardiovascular disease or cerebrovascular disease). Parkinson's patients being treated with dopaminergic agonists ordinarily require careful monitoring for signs and symptoms of postural hypotension, especially during dose escalation, and should be informed of this risk.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pleural/retroperitoneal fibrosis: Ergot-derived dopamine agonists have been associated with fibrotic complications (eg, retroperitoneal fibrosis, pleural thickening, and pulmonary infiltrates). Although pramipexole is not an ergot, there have been postmarketing reports of possible fibrotic complications (peritoneal, pleural, pulmonary) with pramipexole; monitor closely for signs and symptoms of fibrosis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Retinal changes: Pathologic degenerative changes were observed in the retinas of albino rats during studies with this agent, but were not observed in the retinas of albino mice or in other species. The significance of these data for humans remains uncertain.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Somnolence: Patients have reported falling asleep while engaging in activities of daily living; this has been reported to occur without significant warning signs. Monitor for daytime somnolence or pre-existing sleep disorder; caution with concomitant sedating medication; discontinue if significant daytime sleepiness or episodes of falling asleep occur. Patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving). Use with caution in patients receiving other CNS depressants or psychoactive agents. Effects with other sedative drugs or ethanol may be potentiated. Pramipexole has been associated with somnolence, particularly at higher dosages (&gt;1.5 mg/day).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment; dose adjustment may be necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Restless legs syndrome (RLS): Augmentation (earlier onset of symptoms in the evening/afternoon, increase and/or spread of symptoms to other extremities) or rebound (shifting of symptoms to early morning hours) may occur in some RLS patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: May be prone to an increased risk of adverse drug reactions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Discontinuation of therapy: Taper gradually when discontinuing therapy in Parkinson&rsquo;s disease; dopaminergic agents have been associated with a syndrome resembling neuroleptic malignant syndrome on abrupt withdrawal or significant dosage reduction after long-term use.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299931\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F212283\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): May enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotics (Atypical): May diminish the therapeutic effect of Anti-Parkinson's Agents (Dopamine Agonist). Management: Consider using an alternative antipsychotic agent when possible in patients with Parkinson's disease.  If an atypical antipsychotic is necessary, consider using clozapine or quetiapine, which may convey the lowest interaction risk.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotics (Typical): Anti-Parkinson's Agents (Dopamine Agonist) may diminish the therapeutic effect of Antipsychotics (Typical). Antipsychotics (Typical) may diminish the therapeutic effect of Anti-Parkinson's Agents (Dopamine Agonist).  Management: Avoid concomitant therapy if possible and monitor for decreased effects of both agents when these combinations cannot be avoided. Atypical antipsychotics such as clozapine and quetiapine may be less likely to reduce the effects of anti-Parkinson's agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cimetidine: May increase the serum concentration of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: May enhance the adverse/toxic effect of Anti-Parkinson's Agents (Dopamine Agonist).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoclopramide: May diminish the therapeutic effect of Anti-Parkinson's Agents (Dopamine Agonist).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F212306\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: May increase CNS depression; monitor for increased effects with coadministration. Caution patients about effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Food intake does not affect the extent of drug absorption although the time to maximal plasma concentration is delayed when taken with a meal.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: Avoid valerian, St John's wort, SAMe, kava kava (may increase risk of serotonin syndrome and/or excessive sedation).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F212284\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F212297\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Early embryonic loss and postnatal growth inhibition were observed in animal studies. There are no adequate and well-controlled studies in pregnant women.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F212318\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F212298\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prolactin secretion may be inhibited.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F212299\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be taken with or without food. May be taken with food to decrease nausea.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F212296\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, 24-hour",
"     </b>",
"     (Mirapex ER Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.375 mg (7): $103.92",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.75 mg (7): $103.92",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1.5 mg (7): $103.92",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2.25 mg (30): $445.40",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     3 mg (30): $445.40",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     3.75 mg (30): $445.40",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4.5 mg (30): $445.40",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Mirapex Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.125 mg (90): $470.74",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.25 mg (90): $470.74",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.5 mg (90): $470.74",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.75 mg (90): $470.74",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 mg (90): $470.74",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1.5 mg (90): $470.74",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Pramipexole Dihydrochloride Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.125 mg (90): $265.47",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.25 mg (90): $265.47",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.5 mg (90): $265.47",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.75 mg (90): $265.47",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 mg (90): $265.47",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1.5 mg (90): $265.47",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F212286\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blood pressure, heart rate; body weight changes; CNS depression, fall risk, skin changes, behavior changes (eg, compulsive behaviors)",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F212300\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Mirapex (AR, BR, CN, KP, TW, VE);",
"     </li>",
"     <li>",
"      Mirapexin (AT, BE, BG, CH, CZ, DE, DK, FI, FR, GB, GR, HN, IE, IT, NL, NO, PL, PT, RU, SE, TR);",
"     </li>",
"     <li>",
"      Pexola (CO, UY);",
"     </li>",
"     <li>",
"      Sifrol (AE, AR, AT, BE, BG, BH, BR, CH, CL, CN, CY, CZ, DE, DK, EG, FI, FR, GB, GR, HN, ID, IE, IL, IQ, IR, IT, JO, KW, LB, LY, MX, MY, NL, NO, OM, PE, PH, PT, PY, QA, RU, SA, SE, SG, SY, TR, VE, YE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F212278\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Pramipexole is a nonergot dopamine agonist with specificity for the D",
"     <sub>",
"      2",
"     </sub>",
"     subfamily dopamine receptor, and has also been shown to bind to D",
"     <sub>",
"      3",
"     </sub>",
"     and D",
"     <sub>",
"      4",
"     </sub>",
"     receptors. By binding to these receptors, it is thought that pramipexole can stimulate dopamine activity on the nerves of the striatum and substantia nigra.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F212293\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Rapid",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 500 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: ~15%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Negligible (&lt;10%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Immediate release: &gt;90%; Extended release (as compared to immediate release): 100%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 8.5 hours; Elderly: 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: Immediate release: ~2 hours; Extended release: 6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (90% as unchanged drug)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Aiken CB, &ldquo;Pramipexole In Psychiatry: A Systematic Review Of The Literature,&rdquo;",
"      <i>",
"       J Clin Psychiatry",
"      </i>",
"      , 2007, 68(8):1230-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/19/32055/abstract-text/17854248/pubmed\" id=\"17854248\" target=\"_blank\">",
"        17854248",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Carville SF, Arendt-Nielsen S, Bliddal H, et la, &ldquo;EULAR Evidence-Based Recommendations for the Management of Fibromyalgia Syndrome,&rdquo;",
"      <i>",
"       Ann Rheum Dis",
"      </i>",
"      , 2008, 67(4):536-41.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/19/32055/abstract-text/17644548/pubmed\" id=\"17644548\" target=\"_blank\">",
"        17644548",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Factor SA, &ldquo;Current Status of Symptomatic Medical Therapy in Parkinson&rsquo;s Disease,&rdquo;",
"      <i>",
"       Neurotherapeutics",
"      </i>",
"      , 2008, 5(2):164-80.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/19/32055/abstract-text/18394561/pubmed\" id=\"18394561\" target=\"_blank\">",
"        18394561",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Goldberg JF, Burdick KE, and Endick CJ, &ldquo;Preliminary Randomized, Double-Blind, Placebo-Controlled Trial of Pramipexole Added to Mood Stabilizers for Treatment-Resistant Bipolar Depression,&rdquo;",
"      <i>",
"       Am J Psychiatry",
"      </i>",
"      , 2004, 161(3):564-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/19/32055/abstract-text/14992985/pubmed\" id=\"14992985\" target=\"_blank\">",
"        14992985",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Guttman M, &ldquo;Double-Blind Comparison of Pramipexole and Bromocriptine Treatment With Placebo in Advanced Parkinson's Disease,&rdquo; International Pramipexole-Bromocriptine Study Group,",
"      <i>",
"       Neurology",
"      </i>",
"      , 1997, 49(4):1060-5.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Holman AJ and Myers RR, &ldquo;A Randomized, Double-Blind, Placebo-Controlled Trial of Pramipexole, a Dopamine Agonist, in Patients With Fibromyalgia Receiving Concomitant Medications,&rdquo;",
"      <i>",
"       Arthritis Rheum",
"      </i>",
"      , 2005, 52(8):2495-505.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/19/32055/abstract-text/16052595/pubmed\" id=\"16052595\" target=\"_blank\">",
"        16052595",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lieberman A, Ranhosky A, and Korts D,  &ldquo;Clinical Evaluation of Pramipexole in Advanced Parkinson's Disease: Results of a Double-Blind, Placebo-Controlled, Parallel-Group Study,&rdquo;",
"      <i>",
"       Neurology",
"      </i>",
"      , 1997, 49(1):162-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/19/32055/abstract-text/9222185/pubmed\" id=\"9222185\" target=\"_blank\">",
"        9222185",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Molho ES, Factor SA, Weiner WJ, et al, &ldquo;The Use of Pramipexole, a Novel Dopamine (DA) Agonist, in Advanced Parkinson's Disease,&rdquo;",
"      <i>",
"       J Neural Trans",
"      </i>",
"      , 1995, 45(Suppl):225-30.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Molina JA, S&agrave;inz-Artiga MJ, Fraile A, et al, &ldquo;Pathologic Gambling in Parkinson's Disease: A Behavioral Manifestation of Pharmacologic Treatment,&rdquo;",
"      <i>",
"       Mov Disord",
"      </i>",
"      , 2000, 15(5):869-72.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/19/32055/abstract-text/11009192/pubmed\" id=\"11009192\" target=\"_blank\">",
"        11009192",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Piercey MF, Hoffman WE, Smith MW, et al, &ldquo;Inhibition of Dopamine Neuron Firing by Pramipexole, a Dopamine D(3) Receptor-Preferring Agonist: Comparison to Other Dopamine Receptor Agonists,&rdquo;",
"      <i>",
"       Eur J Pharmacol",
"      </i>",
"      , 1996, 312(1):35-44.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/19/32055/abstract-text/8891576/pubmed\" id=\"8891576\" target=\"_blank\">",
"        8891576",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;RLS Medical Bulletin,&rdquo; Restless Legs Syndrome Foundation, 2005, 1-34. Available at www.rls.org . Last accessed September 11, 2012.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Safety and Efficacy of Pramipexole in Early Parkinson Disease. Parkinson Study Group,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 1997, 278(2):125-30.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/19/32055/abstract-text/9214527/pubmed\" id=\"9214527\" target=\"_blank\">",
"        9214527",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Shannon KM, Bennet JP Jr, and Friedman JH, &ldquo;Efficacy of Pramipexole, A Novel Dopamine Agonist, as Monotherapy in Mild to Moderate Parkinson's Disease,&rdquo; The Pramipexole Study Group,",
"      <i>",
"       Neurology",
"      </i>",
"      , 1997, 49(3):724-8.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Silber MH, Girish M, and Izurieta R, &ldquo;Pramipexole in the Management of Resless Legs Syndrome: An Extended Study,&rdquo;",
"      <i>",
"       Sleep",
"      </i>",
"      , 2003, 26(7):819-21.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/19/32055/abstract-text/14655914/pubmed\" id=\"14655914\" target=\"_blank\">",
"        14655914",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Stern MB, &ldquo;Contemporary Approaches to the Pharmacotherapeutic Management of Parkinson's Disease: An Overview,&rdquo;",
"      <i>",
"       Neurology",
"      </i>",
"      , 1997, 49(1 Suppl 1):2-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/19/32055/abstract-text/9222162/pubmed\" id=\"9222162\" target=\"_blank\">",
"        9222162",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ting RM and Force RW, &ldquo;Pramipexole for Parkinson's Disease,&rdquo;",
"      <i>",
"       J Fam Pract",
"      </i>",
"      , 1998, 46(1):19-20.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/19/32055/abstract-text/9451363/pubmed\" id=\"9451363\" target=\"_blank\">",
"        9451363",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Watts RL, &ldquo;The Role of Dopamine Agonists in Early Parkinson's Disease,&rdquo;",
"      <i>",
"       Neurology",
"      </i>",
"      , 1997, 49(1 Suppl 1):34-48.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Weintraub D, Siderowf AD, Potenza MN, et al, &ldquo;Association of Dopamine Agonist Use With Impulse Control Disorders in Parkinson Disease,&rdquo;",
"      <i>",
"       Arch Neurol",
"      </i>",
"      , 2006, 63(7):969-73.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/19/32055/abstract-text/16831966/pubmed\" id=\"16831966\" target=\"_blank\">",
"        16831966",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Winkelman JW and Johnston L, &ldquo;Augmentation and Tolerance With Long-Term Pramipexole Treatment of Restless Legs Syndrome (RLS),&rdquo;",
"      <i>",
"       Sleep Med",
"      </i>",
"      , 2004, 5(1):9-14.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/19/32055/abstract-text/14725821/pubmed\" id=\"14725821\" target=\"_blank\">",
"        14725821",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9560 Version 42.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-115.66.252.144-C3286EAA3D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_19_32055=[""].join("\n");
var outline_f31_19_32055=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15054175\">",
"      Special Alerts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212309\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212310\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212335\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212313\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212314\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212315\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15028352\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212288\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212275\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212291\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212289\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212331\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212341\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212333\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212294\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212279\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299931\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212283\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212306\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212284\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212297\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212318\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212298\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212299\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212296\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212286\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212300\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212278\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212293\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9560\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9560|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?35/4/35908?source=related_link\">",
"      Pramipexole: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_19_32056="Hemorrhagic endovasculitis";
var content_f31_19_32056=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F50997&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F50997&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 560px\">",
"   <div class=\"ttl\">",
"    Hemorrhagic endovasculitis in the stem villus of a liveborn infant with cardiac failure",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 540px; height: 384px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Drucilla Roberts, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_19_32056=[""].join("\n");
var outline_f31_19_32056=null;
var title_f31_19_32057="Approach to the patient with vertigo";
var content_f31_19_32057=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Approach to the patient with vertigo",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/19/32057/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/19/32057/contributors\">",
"     Joseph M Furman, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/19/32057/contributors\">",
"     Jason JS Barton, MD, PhD, FRCPC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/19/32057/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/19/32057/contributors\">",
"     Michael J Aminoff, MD, DSc",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/19/32057/contributors\">",
"     Robert S Hockberger, MD, FACEP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/19/32057/contributors\">",
"     Daniel G Deschler, MD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/19/32057/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/19/32057/contributors\">",
"     Janet L Wilterdink, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?31/19/32057/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 7, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vertigo is a symptom of illusory movement. Almost everyone has experienced vertigo as the transient spinning dizziness immediately after turning around rapidly several times. Vertigo can also be a sense of swaying or tilting. Some perceive self-motion whereas others perceive motion of the environment.",
"   </p>",
"   <p>",
"    Vertigo is a symptom, not a diagnosis. It arises because of asymmetry in the vestibular system due to damage to or dysfunction of the labyrinth, vestibular nerve, or central vestibular structures in the brainstem.",
"   </p>",
"   <p>",
"    Vertigo is a troubling problem for many clinicians because it is symptomatic of a large range of diagnoses from benign to immediately life threatening (",
"    <a class=\"graphic graphic_table graphicRef66539 \" href=\"mobipreview.htm?24/29/25051\">",
"     table 1",
"    </a>",
"    ). However, in most cases, the clinical history, especially the tempo of the symptoms (",
"    <a class=\"graphic graphic_table graphicRef81596 \" href=\"mobipreview.htm?9/14/9453\">",
"     table 2",
"    </a>",
"    ), with examination findings that distinguish between central and peripheral etiologies (",
"    <a class=\"graphic graphic_table graphicRef76359 \" href=\"mobipreview.htm?29/33/30235\">",
"     table 3",
"    </a>",
"    ) identify those patients that require urgent diagnostic evaluation.",
"   </p>",
"   <p>",
"    Vertigo is only one type of dizziness. Other disorders that present with dizziness include presyncopal faintness, disequilibrium, and nonspecific or ill-defined light-headedness. The initial approach to the patient who complains of dizziness is to localize the cause of the symptom into one of these broad categories. This is described separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/43/23223?source=see_link\">",
"     \"Approach to the patient with dizziness\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This topic will discuss the clinical approach to a patient with vertigo. The pathophysiology, etiology, and treatment of vertigo are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/38/17001?source=see_link\">",
"     \"Pathophysiology, etiology, and differential diagnosis of vertigo\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/15/13559?source=see_link\">",
"     \"Treatment of vertigo\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     HISTORY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The history should allow the clinician to distinguish vertigo from other types of dizziness and to make a hypothesis about the site and type of lesion. It is customary to organize causes of vertigo into peripheral and central disorders (",
"    <a class=\"graphic graphic_table graphicRef66539 \" href=\"mobipreview.htm?24/29/25051\">",
"     table 1",
"    </a>",
"    ). These have distinctive clinical features, but with some overlap. The clinical features of the most common disorders are summarized in the Table (",
"    <a class=\"graphic graphic_table graphicRef81596 \" href=\"mobipreview.htm?9/14/9453\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Vertigo",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vertigo is the predominant symptom of vestibular dysfunction. Patients often experience vertigo as an illusion of motion; some interpret this as self-motion, others as motion of the environment. The most common motion illusion is a spinning sensation.",
"   </p>",
"   <p>",
"    A spinning sensation is not required; vertigo can also be a sense of swaying or tilting. Also, not all patients are able to describe their vertigo in such concrete terms. Vague dizziness, imbalance, or disorientation may eventually prove to be due to a vestibular problem [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/19/32057/abstract/1\">",
"     1",
"    </a>",
"    ]. On the other hand, some patients with presyncope sometimes interpret the woozy, faint feeling as a spinning sensation.",
"   </p>",
"   <p>",
"    Severe vertigo may occur with both acute central and peripheral lesions. However, when symptoms are less pronounced, particularly when there is pronounced nystagmus out of proportion to the severity of vertigo, this strongly suggests a brainstem rather than a peripheral lesion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Nausea and vomiting",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nausea and vomiting are typical with acute vertigo, unless it is mild or very brief, as with benign paroxysmal positional vertigo. Vomiting can be severe, causing dehydration and electrolyte imbalance. Severe nausea and vomiting are more common with peripheral than central lesions but can occur with both [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/19/32057/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Postural instability",
"    </span>",
"    &nbsp;&mdash;&nbsp;Postural stability can be affected in patients with vertigo. The vestibular nuclei send signals to the vestibulospinal tract, which in turn stimulates antigravity muscles that maintain posture.",
"   </p>",
"   <p>",
"    The effects of unilateral lesions of the vestibular apparatus upon postural stability are variable. In general, vertigo of central origin impairs gait and posture to a greater degree than does vertigo of peripheral origin, probably because central etiologies likely also impair other pathways involved in balance and posture [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/19/32057/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Patients with vertigo of peripheral origin are usually able to walk, but may be very reluctant to move.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Time course",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vertigo is never a permanent, continuous symptom. Even when the vestibular lesion is permanent, the central nervous system adapts to the defect so that vertigo subsides over days or weeks. Constant dizziness lasting months is not vestibular. However, some patients describe constant dizziness but actually mean that they have a constant susceptibility to frequent episodic dizziness.",
"   </p>",
"   <p>",
"    Vertigo can occur as single or recurrent episodes and may last seconds, hours, or days. This time course of symptoms provides one of the best clues to the underlying pathophysiology of vertigo (",
"    <a class=\"graphic graphic_table graphicRef81596 \" href=\"mobipreview.htm?9/14/9453\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Recurrent vertigo lasting under one minute is usually benign paroxysmal positional vertigo [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/19/32057/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A single episode of vertigo lasting several minutes to hours may be due to migraine or to transient ischemia of the labyrinth or brainstem [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/19/32057/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The recurrent episodes of vertigo associated with Meniere disease or recurrent vestibulopathy also typically last hours but can be briefer [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/19/32057/abstract/5,6\">",
"       5,6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      More prolonged, severe episodes of vertigo that occur with vestibular neuritis can last for days [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/19/32057/abstract/7,8\">",
"       7,8",
"      </a>",
"      ]. This is also characteristic for vertigo originating from multiple sclerosis or infarction of the brainstem or cerebellum.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Aggravating and provoking factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;All vertigo is made worse by moving the head. Many patients in the midst of a vertiginous attack may be petrified to move. If head motion does not worsen the feeling, it is probably another type of dizziness. This feature does not distinguish causes of vertigo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/19/32057/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Attacks of benign paroxysmal positional vertigo are often provoked with specific head movements or postures (eg, rolling over in bed, extending the neck).",
"   </p>",
"   <p>",
"    Vertigo aggravated by coughing, sneezing, exertion, or loud noises (Tullio phenomenon) should raise suspicion of either a perilymphatic fistula, in which there is an abnormal connection between the middle ear and the perilymphatic space of the inner ear, or a superior canal dehiscence, in which there is a defect in the roof of the superior canal. Both conditions allow pressure to be transmitted from the cerebrospinal fluid (CSF) space to the inner ear [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/19/32057/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/38/17001?source=see_link\">",
"     \"Pathophysiology, etiology, and differential diagnosis of vertigo\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Head trauma is an important historical feature and can produce vertigo by a variety of mechanisms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/19/32057/abstract/12\">",
"     12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/59/29626?source=see_link&amp;anchor=H20#H20\">",
"     \"Concussion and mild traumatic brain injury\", section on 'Post-traumatic vertigo'",
"    </a>",
"    .) Barotrauma, middle ear surgery, and straining with weight lifting and bowel movements have also been reported to produce a perilymphatic fistula.",
"   </p>",
"   <p>",
"    Recent hyperextension injury to the neck, usually with persistent neck pain, suggests the possibility of vertebral artery dissection with brainstem or labyrinthine ischemia.",
"   </p>",
"   <p>",
"    Recent viral symptoms may suggest acute vestibular neuritis, which is believed to be produced by viral or postviral inflammation of the eighth cranial nerve. However, a history of recent viral illness is both nonspecific and insensitive; less than one-half of patients with vestibular neuritis will report this [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/19/32057/abstract/7,13,14\">",
"     7,13,14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Associated symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of associated symptoms may help to distinguish the etiology of vertigo:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acute vertigo due to a vertebrobasilar stroke is almost always accompanied by other evidence of brainstem ischemia such as diplopia, dysarthria, dysphagia, weakness, or numbness [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/19/32057/abstract/1\">",
"       1",
"      </a>",
"      ]. However, infarction of the cerebellum may present as vertigo with no other symptoms. Focal neck pain may suggest vertebral artery dissection.",
"     </li>",
"     <li>",
"      Vertigo in patients with multiple sclerosis may also be preceded by or associated with other neurologic dysfunction depending on the locus of demyelination.",
"     </li>",
"     <li>",
"      Deafness and tinnitus suggest a peripheral lesion of the inner ear. A sensation of aural fullness typically accompanies attacks of Meniere disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/19/32057/abstract/6\">",
"       6",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/61/32729?source=see_link\">",
"       \"Meniere disease\"",
"      </a>",
"      .) A pressure sensation in the ear and high frequency sensorineural hearing loss can be associated with the development of a traumatic perilymphatic fistula [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/19/32057/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Headache, photophobia, and sonophobia suggest migrainous vertigo. Most patients with migrainous vertigo will also experience visual aura in at least some of their attacks.",
"     </li>",
"     <li>",
"      Shortness of breath, palpitations, and sweating may suggest a panic attack, but true vertigo is often so terrifying that such symptoms are not uncommon with vestibular disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/19/32057/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Prior medical history",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A prior history of migraine suggests that this may be the etiology of vertigo.",
"     </li>",
"     <li>",
"      The presence of stroke risk factors such as hypertension, diabetes mellitus, smoking, and a history of vascular disease support a diagnosis of vertebrobasilar ischemia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/19/32057/abstract/1\">",
"       1",
"      </a>",
"      ]. Patients with an episode of vertigo and one or more risk factors have a substantial risk of subsequent stroke: an 8 percent 2-year risk with one or two risk factors and 14 percent 2-year risk with three or more risk factors [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/19/32057/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Past head trauma is a common antecedent to benign paroxysmal positional vertigo. Less commonly, head trauma or barotrauma can cause a perilymphatic fistula.",
"     </li>",
"     <li>",
"      A family history of vertigo may suggest a rare hereditary channelopathy.",
"     </li>",
"     <li>",
"      Certain medications are associated with vestibular (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      , aminoglycosides) or cerebellar (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/48/35594?source=see_link\">",
"       phenytoin",
"      </a>",
"      ) toxicity.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Other symptoms of vestibular dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with vestibular injury may not complain of vertigo. In fact, vertigo is unusual in chronic vestibular injury or acute, bilaterally symmetric vestibular injury. Other symptoms of vestibular injury may include:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Tilt illusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;A tilt illusion in which patients feel that they and their environment are tilted with respect to gravity, even to the point of being upside down, usually reflects damage to otolithic organs (utricle and saccule) or their central connections. Otolith dysfunction may also cause lateropulsion or the tendency to fall to the side of the lesion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Drop attacks",
"    </span>",
"    &nbsp;&mdash;&nbsp;Drop attacks are attributed to a sudden loss of tone mediated by vestibulospinal reflexes. Unlike presyncope and seizures, there is no faintness or loss of consciousness with drop attacks. Patients with drop attacks of vestibular origin often have a sensation of being pushed or pulled to the ground [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/19/32057/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. Drop attacks are an unusual feature of Meniere disease. Sometimes called Tumarkins' otolithic crises, this symptom is usually seen only in advanced cases. Superior canal dehiscence and aminoglycoside toxicity are also associated with this presentation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/19/32057/abstract/19,20\">",
"     19,20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Spatial disorientation",
"    </span>",
"    &nbsp;&mdash;&nbsp;A fleeting spatial disorientation with rapid head turns often remains after the patient has recovered from an acute attack of vertigo. The most astute patients will observe that this is more pronounced with head turns to the side of the lesion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Oscillopsia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oscillopsia, a visual illusion of to-and-fro environmental motion, and blurred vision whenever the head is in motion is a manifestation of an impaired vestibuloocular reflex. Affected patients notice that everything jiggles when they are walking or driving on rough pavement; they often have to stop and stand still to read signs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Impaired balance without vertigo",
"    </span>",
"    &nbsp;&mdash;&nbsp;This is a common manifestation of acute simultaneous bilateral vestibular loss such as that occurring with aminoglycoside antibiotic toxicity. Vertigo does not occur because there is no marked vestibular asymmetry. Symptoms are most marked in the dark when visual cues to position in space are not available. Aminoglycoside toxicity is the most common identified etiology of bilateral vestibulopathy, followed by Meniere disease and meningitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/19/32057/abstract/21\">",
"     21",
"    </a>",
"    ]. Most cases, however, are cryptogenic in origin. This presentation is also characteristic of acute midline cerebellar lesions or thiamine deficiency. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/62/10217?source=see_link\">",
"     \"Wernicke's encephalopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     EXAMINATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The physical examination should confirm vestibular dysfunction and distinguish central from peripheral causes of vertigo. Features most helpful in distinguishing central and peripheral vertigo are shown in the Table (",
"    <a class=\"graphic graphic_table graphicRef76359 \" href=\"mobipreview.htm?29/33/30235\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Nystagmus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nystagmus is a rhythmic oscillation of the eyes. There are many types of nystagmus. Some types of nystagmus suggest that a patient's complaint of vertigo originates from pathology in the vestibular system.",
"   </p>",
"   <p>",
"    An important role of the vestibular system is to maintain gaze during head movement through the vestibular ocular reflexes. Acute unilateral vestibular lesions lead to a pathologic asymmetry in vestibular activity. This results in a slow drift of the eyes away from the target in one direction, followed by a fast corrective movement in the reverse direction. The eyes appear to \"beat\" in the direction of the fast phase. This nystagmus, which is often labeled &ldquo;spontaneous nystagmus&rdquo;, continues until the asymmetry of vestibular activity is restored to normal or until the central nervous system adapts to the vestibular lesion. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/23/34165?source=see_link\">",
"     \"Overview of nystagmus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a patient with acute vertigo, nystagmus is usually visible with the patient looking straight ahead. If the lesion is peripheral, the fast phase is away from the affected side. Usually, nystagmus increases in frequency and amplitude with gaze toward the side of the fast phase, eg, leftward gaze increases left-beating nystagmus, if present.",
"   </p>",
"   <p>",
"    Other features of the nystagmus have localizing value for central versus peripheral vertigo (",
"    <a class=\"graphic graphic_table graphicRef76359 \" href=\"mobipreview.htm?29/33/30235\">",
"     table 3",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Type of nystagmus. A mixed horizontal-torsional nystagmus results if a peripheral lesion affects all three semicircular canals on one side. The horizontal fast phases beat toward the normal ear, as do the upper poles of the eyes for the torsional fast phases. The nystagmus from peripheral disease occasionally appears purely horizontal, but it is never purely torsional or vertical. The nystagmus with central lesions may have any trajectory.",
"     </li>",
"     <li>",
"      Visual fixation tends to suppress nystagmus that is due to a peripheral lesion, but it does not usually suppress nystagmus from a central lesion. It may be useful to inhibit visual fixation to test whether the nystagmus is central or peripheral in origin. Frenzel lenses are large magnifiers that blur vision and prevent visual fixation. A peripheral lesion is likely if nystagmus increases when Frenzel lenses are in place. The effect of fixation can also be determined during ophthalmoscopy if the examiner covers and uncovers the other eye. One group of investigators has proposed that examination with a penlight (substituting for the ophthalmoscope) may also allow examination for nystagmus with and without fixation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/19/32057/abstract/22\">",
"       22",
"      </a>",
"      ]. A peripheral disorder is likely if nystagmus increases on covering the fixating eye. In the ophthalmoscopic examination, the direction of nystagmus appears reversed, because the optic head is behind the center of eye rotation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/19/32057/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Testing nystagmus in different gaze positions can provide other localizing clues. In peripheral lesions, the predominant direction of nystagmus remains the same in all directions of gaze. Nystagmus that reverses direction when the patient looks right then left suggests a central abnormality. However, the absence of this feature does not rule out a central cause of vertigo. Nystagmus that reverses direction with convergence also suggests a central lesion.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Gait instability",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unilateral peripheral disorders generally cause patients to lean or fall toward the side of the lesion. Patients may be uncomfortable and reluctant to move because of their vertigo, but they are still able to walk. Romberg testing will cause the patients to fall or tilt to one side.",
"   </p>",
"   <p>",
"    Patients with an acute cerebellar stroke are often unable to walk without falling. The direction of tilting or falling with Romberg testing may vary.",
"   </p>",
"   <p>",
"    While the ability to walk and the direction of falling may provide useful clues to the origin of vertigo, in practice, it may be difficult to persuade a patient with severe vertigo to attempt to walk.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Other neurologic signs",
"    </span>",
"    &nbsp;&mdash;&nbsp;A careful neurologic examination should be performed since the presence of additional neurologic abnormalities strongly suggests the presence of a central lesion. A search should be made for cranial nerve abnormalities, motor or sensory changes, dysmetria, or abnormal reflexes. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/30/38377?source=see_link\">",
"     \"The detailed neurologic examination in adults\"",
"    </a>",
"    .) In particular, the abnormal facial sensation, ptosis, and diplopia of a lateral medullary infarction may be overlooked by both patients and clinicians when the vertigo is profound. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/38/17001?source=see_link&amp;anchor=H22#H22\">",
"     \"Pathophysiology, etiology, and differential diagnosis of vertigo\", section on 'Wallenberg's syndrome'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/22/39273?source=see_link&amp;anchor=H8#H8\">",
"     \"Posterior circulation cerebrovascular syndromes\", section on 'Lateral medullary infarction'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, the absence of other neurologic signs does not exclude a central process. In particular, a midline or inferior cerebellar infarction may produce no neurologic signs other than nystagmus and gait instability on examination.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Office hearing tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bedside tests of hearing and an examination of the tympanic membrane can be useful in distinguishing the etiology of vertigo. The otoscopic examination provides evidence of acute or chronic otitis media.",
"   </p>",
"   <p>",
"    The examiner can easily test hearing by several methods. One is to softly whisper into each ear and then ask the patient to repeat what was whispered. Another is to hold the examiner's hands next to the patient's ears but out of the patient's eyesight. The examiner then rubs the fingers together on one side, with a sham rubbing movement on the opposite side, and asks the patient to report when the finger scratching sound is heard and from which ear it is heard. Another method is to vibrate a 512 Hz tuning fork, placing it close to one ear and then the other in rapid succession so that the patient can compare the loudness.",
"   </p>",
"   <p>",
"    The Weber and Rinne tests are used to distinguish conductive and sensorineural hearing loss (",
"    <a class=\"graphic graphic_table graphicRef74212 \" href=\"mobipreview.htm?13/29/13787\">",
"     table 4",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the Weber test, a vibrating tuning fork is placed on the forehead in the midline. With normal hearing, the sound is heard equally in both ears. With sensorineural hearing loss, the sound localizes to the normal ear. With conductive hearing loss, the sound localizes to the affected ear (",
"      <a class=\"graphic graphic_figure graphicRef58032 \" href=\"mobipreview.htm?40/5/41043\">",
"       figure 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef74212 \" href=\"mobipreview.htm?13/29/13787\">",
"       table 4",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      The Rinne test looks for conductive hearing loss. The tuning fork is placed on the mastoid bone behind the ear of the affected side in order to test bone conduction of sound. The vibrating tuning fork is then placed about 2.5 cm from the ear to test air conduction. Normally, air conduction of sound is better than bone conduction, and the sound is heard louder next to the ear than when placed on the mastoid. With conductive hearing loss, the tuning fork is heard less well or not at all when the tuning fork is adjacent to the ear. With sensorineural hearing loss, both air and bone conduction may be quantitatively decreased, but air conduction remains better than bone conduction (",
"      <a class=\"graphic graphic_figure graphicRef58032 \" href=\"mobipreview.htm?40/5/41043\">",
"       figure 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef74212 \" href=\"mobipreview.htm?13/29/13787\">",
"       table 4",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Unilateral sensorineural hearing loss suggests a peripheral lesion; audiometry is required for confirmation. If no obvious cause of unilateral sensorineural hearing loss (eg, Meniere disease) has been identified by history, a magnetic resonance imaging (MRI) or CT (computed tomography) scan of the posterior fossa and internal auditory canal is necessary. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/32/39429?source=see_link\">",
"     \"Evaluation of hearing loss in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    While associated hearing loss strongly points to a peripheral origin of vertigo, the absence of hearing loss has less localizing value.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Dix-Hallpike maneuver",
"    </span>",
"    &nbsp;&mdash;&nbsp;Positional maneuvers are designed to reproduce vertigo and elicit nystagmus in patients with a history of positional dizziness. These maneuvers are most useful in patients who do not have symptoms or nystagmus at rest. The Dix-Hallpike maneuver tests for canalithiasis of the posterior semicircular canal, which is the most common cause of benign paroxysmal positional vertigo (BPPV) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/19/32057/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    With the patient sitting, the neck is extended and turned to one side. The patient is then placed supine rapidly, so that the head hangs over the edge of the bed. The patient is kept in this position until 30 seconds have passed if no nystagmus occurs. The patient is then returned to upright, observed for another 30 seconds for nystagmus, and the maneuver is repeated with the head turned to the other side (",
"    <a class=\"graphic graphic_figure graphicRef52232 \" href=\"mobipreview.htm?34/32/35330\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The Dix-Hallpike maneuver will usually provoke paroxysmal vertigo and nystagmus if posterior canal dysfunction is present in the lower ear. The nystagmus and vertigo usually appear after a latency of a few seconds and last less than 30 seconds. It has a typical trajectory, beating horizontally and torsionally, with the upper poles of the eyes beating toward the ground. After the patient sits up, the nystagmus will recur, but in the opposite direction. The maneuver should be repeated to the same side; with each repetition the intensity and duration of nystagmus will diminish, confirming the fatigable nature of the phenomenon. However, repetition of the maneuver can interfere with the ability to immediately perform a therapeutic particle repositioning maneuver; repetition may be deferred when this is being considered. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/13/19673?source=see_link&amp;anchor=H18#H18\">",
"     \"Benign paroxysmal positional vertigo\", section on 'Particle repositioning maneuvers'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The latency, transience, and fatigability, coupled with the typical mixed",
"    <span class=\"nowrap\">",
"     horizontal/rotatory",
"    </span>",
"    direction, are important in diagnosing benign paroxysmal positional vertigo due to posterior canalithiasis (",
"    <a class=\"graphic graphic_table graphicRef73213 \" href=\"mobipreview.htm?18/15/18683\">",
"     table 5",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/19/32057/abstract/7\">",
"     7",
"    </a>",
"    ]. Deviation from these features may occur with rarer types of peripheral positional vertigo but should also raise suspicion of a central lesion. Overall, the sensitivity of the Dix-Hallpike maneuver in patients with BPPV ranges from 50 to 88 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/19/32057/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/13/19673?source=see_link\">",
"     \"Benign paroxysmal positional vertigo\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Other vestibular signs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other signs of vestibular dysfunction can be elicited on examination. The clinical and diagnostic utility of most of these signs is not known, as they have not been systematically studied against a gold standard.",
"   </p>",
"   <p>",
"    These tests are often categorized as to those indicating static vestibular imbalance (spontaneous nystagmus, skew deviation, ocular tilt reaction, and tilt of the subjective visual vertical) and those indicating dynamic vestibular imbalance. The latter implies functional impairment of the vestibuloocular reflex (VOR), which acts to keep the line of sight steady during head movements. This can be detected clinically in four ways: head thrust test, head shaking visual acuity, post-head shaking nystagmus, and caloric tests.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Skew deviation &mdash; A skew deviation is a vertical misalignment of the two eyes resulting from a supranuclear (relative to the ocular motor nuclei) pathology, usually located in the brainstem. This may be caused by a vestibular lesion because of imbalance in otolithic-ocular reflexes. The vertical separation can be tested by placing a red lens over one eye, shining a white point-light at the patient, and asking him or her to note the relative position of the red spot to the white spot. The light should be moved to see how the separation changes with lateral and vertical gaze. Skew deviation is often \"comitant,\" meaning that gaze direction has little effect upon the distance between the images. When it is incomitant, it needs to be differentiated from other problems such as cranial nerve IV nerve palsies. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?24/46/25320?source=see_link\">",
"       \"Overview of diplopia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Ocular tilt reaction &mdash; The ocular tilt reaction (OTR) is a triad of skew deviation, torsional tilt of the eyes with the upper poles tilted toward the eye that is lower, and head tilt toward the eye that is lower.",
"     </li>",
"     <li>",
"      Tilt of the subjective visual vertical &mdash; Tilt of the subjective visual vertical (SVV) is a sensitive sign of static vestibular imbalance [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/19/32057/abstract/26\">",
"       26",
"      </a>",
"      ]. SVV tilt can be measured at the bedside using a simple device made from a bucket with a straight line drawn on the bottom (",
"      <a class=\"graphic graphic_picture graphicRef66460 \" href=\"mobipreview.htm?24/7/24688\">",
"       picture 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/19/32057/abstract/27\">",
"       27",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Skew deviation, OTR, and tilt of the SVV can occur with acute peripheral vestibular lesions or with acute central lesions involving the cerebellum or brainstem vestibular pathways [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/19/32057/abstract/28-30\">",
"       28-30",
"      </a>",
"      ]. Lesions of the peripheral vestibular system or medulla cause a skew deviation with the ipsilateral eye lower and extorted (ipsiversive), along with an ipsiversive tilt of SVV. Lesions of the midbrain cause the opposite (contraversive). Cerebellar lesions, which involve the dentate nucleus, also cause contraversive OTR, while those that spare the dentate nucleus can cause an ipsiversive OTR [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/19/32057/abstract/29,31\">",
"       29,31",
"      </a>",
"      ]. Patients with these manifestations may complain of vertical diplopia but may also experience a tilt illusion of their vision [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/19/32057/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Head thrust test &mdash; The head thrust test (or head impulse test) is performed by instructing the patient to keep his or her eyes on a distant target while wearing his usual prescription eyeglasses. The head is then turned quickly and unpredictably by the examiner, about 15&ordm;; the starting position should be about 10&ordm; from straight ahead.",
"      <br/>",
"      <br/>",
"      The normal response is that the eyes remain on the target (",
"      <a class=\"graphic graphic_figure graphicRef52022 \" href=\"mobipreview.htm?17/19/17715\">",
"       figure 3",
"      </a>",
"      ). The abnormal response is that the eyes are dragged off of the target by the head turn (in one direction), followed by a saccade back to the target after the head turn; this response indicates a deficient VOR on the side of the head turn, implying a peripheral vestibular lesion (inner ear or vestibular nerve) on that side [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/19/32057/abstract/8,32\">",
"       8,32",
"      </a>",
"      ]. Use of videonystagmography can aid in the interpretation and accuracy of this test [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/19/32057/abstract/33\">",
"       33",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      For distinguishing vestibular dysfunction from nonvestibular dizziness, the head thrust test is reported to have a higher specificity (82 to 100 percent) than sensitivity (34 to 39 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/19/32057/abstract/34-36\">",
"       34-36",
"      </a>",
"      ]. However, the use of caloric testing as the gold standard in these studies may not be appropriate and may underestimate sensitivity [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/19/32057/abstract/37\">",
"       37",
"      </a>",
"      ]. In one report, flexing the head forward 30&ordm; during the test increased sensitivity to as high as 71 to 84 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/19/32057/abstract/38\">",
"       38",
"      </a>",
"      ]. In one case series, head thrust tests were abnormal in all 14 patients with aminoglycoside vestibulotoxicity [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/19/32057/abstract/39\">",
"       39",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      An abnormal head thrust test is reported to be a useful test to distinguish between central and peripheral vertigo, particularly in the setting of acute prolonged vertigo, when the examiner is trying to differentiate between vestibular neuritis and cerebellar infarction [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/19/32057/abstract/8,32,33\">",
"       8,32,33",
"      </a>",
"      ]. The head thrust test is normal in most patients with isolated cerebellar lesions (31 of 34 in one series) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/19/32057/abstract/40\">",
"       40",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?34/15/35062?source=see_link&amp;anchor=H3#H3\">",
"       \"Vestibular neuritis\", section on 'Clinical manifestations'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Head shaking visual acuity &mdash; Head shaking visual acuity is tested by having the patient look at an eye chart in the distance wearing his or her customary distance eyeglasses. Customary eyeglasses are important since the VOR is calibrated for a given rotational magnification that varies with different strengths of glasses. The patient reads the eye chart while his or her head is shaken continuously over a small range at about 2 Hz. Then, the patient reads the chart again while his or her head is still. Head shaking acuity that is more than four lines worse than the head still acuity indicates a poor VOR.",
"     </li>",
"     <li>",
"      Head shaking nystagmus &mdash; Head shaking nystagmus is elicited by the patient shaking the head from side to side for 15 to 40 seconds with eyes closed or Frenzel lenses in place. The shaking causes vigorous stimulation of the horizontal semicircular canals of both sides; their velocity data are stored in the cerebellum, decaying slowly after the head stops moving. When the shaking stops, the patient then opens his or her eyes and attempts to look straight ahead. If both sides were equally activated, the decay of velocity information will be balanced, and the eyes will be still. If there is unilateral labyrinthine damage, the asymmetrical neural output will generate a nystagmus that beats away from the damaged side. This test will be normal in patients with bilateral symmetric disease, unlike rapid head thrusts or caloric responses. The test is abnormal in patients with unilateral central vestibular lesions.",
"      <br/>",
"      <br/>",
"      Using caloric testing as the gold standard, head shaking nystagmus has a sensitivity of 46 percent and a specificity of 75 percent for the detection of unilateral peripheral or central vestibular lesions [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/19/32057/abstract/41,42\">",
"       41,42",
"      </a>",
"      ]. In series of patients with vestibular neuritis, head shaking nystagmus was present in 95 to 100 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/19/32057/abstract/43,44\">",
"       43,44",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Head shaking nystagmus may also differentiate central and peripheral lesions. While the induced nystagmus is contralateral to the lesion in peripheral vestibulopathy, nystagmus produced by head shaking in patients with medullary lesions is ipsilateral to the lesion, even in cases in which the spontaneous nystagmus is contralateral [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/19/32057/abstract/45\">",
"       45",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Caloric testing &mdash; Caloric testing is performed by infusing warm or cold water into the ear. Otoscopy should be performed first to ensure that cerumen is not obstructing the flow of water to the tympanic membrane and to verify that there is no tympanic membrane perforation. The head of the patient should be tilted at 30&ordm; up from supine for optimal stimulation of the horizontal semicircular canals.",
"      <br/>",
"      <br/>",
"      When warm water at 44&ordm;C is infused into an ear, the normal response is nystagmus with the fast component toward the infused ear. The opposite response occurs when cold water at 30&ordm;C is infused; the normal response is nystagmus with the fast component away from the cold water-infused ear.",
"      <br/>",
"      <br/>",
"      Lack of a response to warm or cold water on one side suggests disease on that side, usually in peripheral lesions. Central vestibular disorders may also cause caloric hyposensitivity, especially if they involve the vestibular root entry in the medulla. This test can cause significant distress, including nausea and vomiting in awake patients; it is rarely performed in the office evaluation of vertigo but may be useful in the vestibular laboratory (see",
"      <a class=\"local\" href=\"#H25\">",
"       'Electronystagmography and video nystagmography'",
"      </a>",
"      below). Caloric testing is also used in the evaluation of coma. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?28/9/28825?source=see_link\">",
"       \"Stupor and coma in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Others &mdash; Hyperventilation can elicit nystagmus in several central and peripheral vestibular pathologies, and may be a particularly sensitive test in patients with cerebellopontine tumors. In one study, ipsilesional hyperventilation-induced nystagmus was found in 84 percent of patients with cerebellopontine tumors compared with 34 percent in other vestibular diseases [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/19/32057/abstract/46\">",
"       46",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC TESTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tests that may be useful in patients with vertigo include brain imaging, electronystagmography (ENG) and videonystagmography (VNG), vestibular evoked myogenic potentials, audiometry, and brainstem auditory evoked potentials. The indications for this more specialized testing (as well as indications for specialist referral) are not precise. The relatively low prevalence of serious disorders should be balanced against their prognostic and treatment implications when deciding whether to order these tests [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/19/32057/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Magnetic resonance imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Brain imaging is indicated when the history and examination suggest either a central cause of vertigo or a vestibular schwannoma (acoustic neuroma) (",
"    <a class=\"graphic graphic_table graphicRef76359 \" href=\"mobipreview.htm?29/33/30235\">",
"     table 3",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/38/17001?source=see_link\">",
"     \"Pathophysiology, etiology, and differential diagnosis of vertigo\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a patient with acute sustained vertigo, it is often difficult to distinguish between a vascular event involving the cerebellum and vestibular neuritis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/19/32057/abstract/47\">",
"     47",
"    </a>",
"    ]. While the latter has a benign course, the former can be acutely life threatening. A younger patient with acute sustained vertigo, with no other neurologic signs or symptoms, and with nystagmus and an examination that is consistent with a peripheral origin (suppression with visual fixation, falling in opposite direction to nystagmus,",
"    <span class=\"nowrap\">",
"     horizontal/torsional",
"    </span>",
"    nystagmus) does not need immediate imaging if there is improvement within 48 hours [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/19/32057/abstract/7\">",
"     7",
"    </a>",
"    ]. However, neuroimaging is indicated if the examination is not entirely consistent with a peripheral lesion, if there are prominent risk factors for stroke, if there are neurologic signs or symptoms, or if there is a new headache accompanying the vertigo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/19/32057/abstract/7,16,47\">",
"     7,16,47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The procedure of choice is magnetic resonance imaging (MRI) and angiography (MRA). MRI can detect infarction in the posterior fossa on the first day. MRA has a specificity and sensitivity exceeding 95 percent in detecting stenosis or occlusion of the posterior circulation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/19/32057/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Computed tomography (CT) scanning with thin cuts through the cerebellum is an alternative when MRI scanning is not available or in patients with metallic implants. The scan is usually normal in the first hours after an infarct and is overall a less sensitive test than MRI for early infarcts and small mass lesions. However, intraparenchymal hemorrhage will usually be evident immediately. A brain CT scan should therefore be performed if the clinical picture is compatible with cerebellar hemorrhage and the MRI scan is not immediately available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Electronystagmography and video nystagmography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Electronystagmography (ENG) uses electrodes to record eye movements. Videonystagmography (VNG) uses video cameras to record eye movements. These techniques record and quantify both spontaneous and induced nystagmus. Most balance disorders centers and many specialists use ENG or VNG to assess vestibular function and ocular motility.",
"   </p>",
"   <p>",
"    Using a battery of tests such as ocular motor screening, positional testing, head impulse testing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/19/32057/abstract/33\">",
"     33",
"    </a>",
"    ], caloric testing, and rotational testing with ENG or VNG can help to discriminate between central and peripheral etiologies. Caloric testing in the vestibular laboratory has a reasonable sensitivity for vestibular disorders, but it does not accurately discriminate between central and vestibular vestibulopathies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/19/32057/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In general, vestibular laboratory testing is indicated when a patient's symptoms do not respond to simple remedies such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/17/37141?source=see_link\">",
"     meclizine",
"    </a>",
"    , persist for more than one to two weeks, or are incapacitating and thus require further diagnostic information.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Vestibular evoked myogenic potentials",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vestibular evoked myogenic potentials (VEMPs) are a new means of assessing otolith function. For cervical VEMPs, which assess saccular function, a loud sound is delivered to one ear while muscular activity is recorded in the ipsilateral sternocleidomastoid muscle. VEMPs are especially useful for detecting superior semicircular canal dehiscence syndrome, which will manifest as a VEMP with a reduced threshold [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/19/32057/abstract/50\">",
"     50",
"    </a>",
"    ]. Another test in development, ocular VEMPs, primarily assess utricular function and records extraocular muscle potentials during head vibration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/19/32057/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Audiometry",
"    </span>",
"    &nbsp;&mdash;&nbsp;Audiometry is more sensitive than office testing to detect hearing loss and can quantify the loss at high and low frequencies. The audiometric battery also establishes if recruitment is present and tests for speech discrimination.",
"   </p>",
"   <p>",
"    Audiometry has limited utility in the diagnosis of patients with vertigo. While conditions such as Meniere disease and vestibular schwannoma are said to have characteristic patterns, the audiometric battery is not truly diagnostic of a specific disorder independently of other factors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/19/32057/abstract/52\">",
"     52",
"    </a>",
"    ]. Nevertheless, the audiogram is sensitive enough to detect unilateral hearing loss in almost all cases of vestibular schwannoma, and may be a useful screening test for this condition [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/19/32057/abstract/53,54\">",
"     53,54",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/18/40232?source=see_link\">",
"     \"Vestibular schwannoma (acoustic neuroma)\"",
"    </a>",
"    .) Also, a finding of low frequency sensorineural hearing loss helps confirm the diagnosis of Meniere disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Brainstem auditory evoked potentials",
"    </span>",
"    &nbsp;&mdash;&nbsp;Brainstem auditory evoked potentials (BAEPs) have a 90 to 95 percent sensitivity for detecting acoustic neuromas. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/18/40232?source=see_link\">",
"     \"Vestibular schwannoma (acoustic neuroma)\"",
"    </a>",
"    .) Any type of sensorineural hearing loss will disrupt the pattern of sound passing from the cochlea to the brainstem; abnormal results are therefore nonspecific [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/19/32057/abstract/53-55\">",
"     53-55",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/13/27863?source=see_link&amp;anchor=H9#H9\">",
"     \"Clinical neurophysiology\", section on 'Auditory evoked potentials'",
"    </a>",
"    .) BAEPs are no longer routinely used in the evaluation of patients with vertigo or suspected vestibular schwannoma.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is customary to organize causes of vertigo into peripheral and central disorders (",
"    <a class=\"graphic graphic_table graphicRef66539 \" href=\"mobipreview.htm?24/29/25051\">",
"     table 1",
"    </a>",
"    ). These have distinctive clinical features, but with some overlap. These clinical features of the more common disorders are summarized in the Table (",
"    <a class=\"graphic graphic_table graphicRef81596 \" href=\"mobipreview.htm?9/14/9453\">",
"     table 2",
"    </a>",
"    ) and are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/38/17001?source=see_link\">",
"     \"Pathophysiology, etiology, and differential diagnosis of vertigo\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?40/59/41905?source=see_link\">",
"       \"Patient information: Vertigo (a type of dizziness) (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?40/31/41460?source=see_link\">",
"       \"Patient information: Dizziness and vertigo (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vertigo is a symptom of illusory movement, most commonly of spinning of oneself or of the environment.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Vertigo can be caused by disorders of the peripheral vestibular system, including the vestibular labyrinth and the vestibular portion of the eighth cranial nerve, or by lesions within the central nervous system, usually the brainstem or cerebellum (",
"      <a class=\"graphic graphic_table graphicRef66539 \" href=\"mobipreview.htm?24/29/25051\">",
"       table 1",
"      </a>",
"      ). Underlying conditions can be benign and self-limiting, or severe and life threatening. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?16/38/17001?source=see_link\">",
"       \"Pathophysiology, etiology, and differential diagnosis of vertigo\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Historical features are helpful in confirming the presence of vertigo and identifying a likely etiology. Of these, the time course of the symptoms is among the most helpful (",
"      <a class=\"graphic graphic_table graphicRef81596 \" href=\"mobipreview.htm?9/14/9453\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'History'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Nystagmus represents the physical manifestation of a patient's complaint of vertigo. Features of the nystagmus: its type (horizontal, torsional, vertical), its tendency to suppress with visual fixation, and whether or not its direction alters with gaze position can suggest a central versus peripheral localization (",
"      <a class=\"graphic graphic_table graphicRef76359 \" href=\"mobipreview.htm?29/33/30235\">",
"       table 3",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Nystagmus'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Other neurologic symptoms: numbness, weakness, pronounced gait impairment, diplopia, and dysarthria point toward a central etiology of vertigo. However, their absence does not rule out a central etiology (",
"      <a class=\"graphic graphic_table graphicRef76359 \" href=\"mobipreview.htm?29/33/30235\">",
"       table 3",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Postural instability'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H19\">",
"       'Other neurologic signs'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The presence of abnormal hearing, tinnitus, or ear pain point toward a peripheral etiology of vertigo. However, their absence does not rule out a peripheral etiology. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Office hearing tests'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The Dix-Hallpike maneuver is most useful to confirm the diagnosis of benign paroxysmal positional vertigo (",
"      <a class=\"graphic graphic_figure graphicRef52232 \" href=\"mobipreview.htm?34/32/35330\">",
"       figure 2",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef73213 \" href=\"mobipreview.htm?18/15/18683\">",
"       table 5",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Dix-Hallpike maneuver'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Magnetic resonance imaging (MRI) and magnetic resonance angiography (MRA) are indicated for patients with suspected central causes of vertigo including those with other signs or symptoms of brainstem dysfunction. In acute sustained vertigo, MRI or CT should be performed urgently to rule out a vascular event in the cerebellum or brainstem in patients who are older, have vascular risk factors, have headache, and whose examination is not completely typical of a peripheral vestibulopathy. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Magnetic resonance imaging'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Audiometry is useful to confirm a diagnosis of Meniere disease and to evaluate hearing loss in other causes of peripheral vertigo. (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Audiometry'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/19/32057/abstract/1\">",
"      Kerber KA, Brown DL, Lisabeth LD, et al. Stroke among patients with dizziness, vertigo, and imbalance in the emergency department: a population-based study. Stroke 2006; 37:2484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/19/32057/abstract/2\">",
"      Baloh RW. Differentiating between peripheral and central causes of vertigo. Otolaryngol Head Neck Surg 1998; 119:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/19/32057/abstract/3\">",
"      Furman JM, Cass SP. Benign paroxysmal positional vertigo. N Engl J Med 1999; 341:1590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/19/32057/abstract/4\">",
"      Baloh RW. Vertebrobasilar insufficiency and stroke. Otolaryngol Head Neck Surg 1995; 112:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/19/32057/abstract/5\">",
"      Saeed SR. Fortnightly review. Diagnosis and treatment of M&eacute;ni&egrave;re's disease. BMJ 1998; 316:368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/19/32057/abstract/6\">",
"      Knox GW, McPherson A. Meni&egrave;re's disease: differential diagnosis and treatment. Am Fam Physician 1997; 55:1185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/19/32057/abstract/7\">",
"      Hotson JR, Baloh RW. Acute vestibular syndrome. N Engl J Med 1998; 339:680.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/19/32057/abstract/8\">",
"      Baloh RW. Clinical practice. Vestibular neuritis. N Engl J Med 2003; 348:1027.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/19/32057/abstract/9\">",
"      Stanton VA, Hsieh YH, Camargo CA Jr, et al. Overreliance on symptom quality in diagnosing dizziness: results of a multicenter survey of emergency physicians. Mayo Clin Proc 2007; 82:1319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/19/32057/abstract/10\">",
"      Minor LB. Superior canal dehiscence syndrome. Am J Otol 2000; 21:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/19/32057/abstract/11\">",
"      Watson SR, Halmagyi GM, Colebatch JG. Vestibular hypersensitivity to sound (Tullio phenomenon): structural and functional assessment. Neurology 2000; 54:722.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/19/32057/abstract/12\">",
"      Marzo SJ, Leonetti JP, Raffin MJ, Letarte P. Diagnosis and management of post-traumatic vertigo. Laryngoscope 2004; 114:1720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/19/32057/abstract/13\">",
"      DIX MR, HALLPIKE CS. The pathology symptomatology and diagnosis of certain common disorders of the vestibular system. Proc R Soc Med 1952; 45:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/19/32057/abstract/14\">",
"      Silvoniemi P. Vestibular neuronitis. An otoneurological evaluation. Acta Otolaryngol Suppl 1988; 453:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/19/32057/abstract/15\">",
"      Yardley L. Overview of psychologic effects of chronic dizziness and balance disorders. Otolaryngol Clin North Am 2000; 33:603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/19/32057/abstract/16\">",
"      Lee CC, Su YC, Ho HC, et al. Risk of stroke in patients hospitalized for isolated vertigo: a four-year follow-up study. Stroke 2011; 42:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/19/32057/abstract/17\">",
"      Lee H, Yi HA, Lee SR, et al. Drop attacks in elderly patients secondary to otologic causes with Meniere's syndrome or non-Meniere peripheral vestibulopathy. J Neurol Sci 2005; 232:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/19/32057/abstract/18\">",
"      Ishiyama G, Ishiyama A, Jacobson K, Baloh RW. Drop attacks in older patients secondary to an otologic cause. Neurology 2001; 57:1103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/19/32057/abstract/19\">",
"      Dallan I, Bruschini L, Nacci A, et al. Drop attacks and vertical vertigo after transtympanic gentamicin: diagnosis and management. Acta Otorhinolaryngol Ital 2005; 25:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/19/32057/abstract/20\">",
"      Brantberg K, Ishiyama A, Baloh RW. Drop attacks secondary to superior canal dehiscence syndrome. Neurology 2005; 64:2126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/19/32057/abstract/21\">",
"      Zingler VC, Cnyrim C, Jahn K, et al. Causative factors and epidemiology of bilateral vestibulopathy in 255 patients. Ann Neurol 2007; 61:524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/19/32057/abstract/22\">",
"      Newman-Toker DE, Sharma P, Chowdhury M, et al. Penlight-cover test: a new bedside method to unmask nystagmus. J Neurol Neurosurg Psychiatry 2009; 80:900.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/19/32057/abstract/23\">",
"      Traccis S, Zoroddu GF, Zecca MT, et al. Evaluating patients with vertigo: bedside examination. Neurol Sci 2004; 25 Suppl 1:S16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/19/32057/abstract/24\">",
"      Hoffman RM, Einstadter D, Kroenke K. Evaluating dizziness. Am J Med 1999; 107:468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/19/32057/abstract/25\">",
"      Froehling DA, Silverstein MD, Mohr DN, et al. Benign positional vertigo: incidence and prognosis in a population-based study in Olmsted County, Minnesota. Mayo Clin Proc 1991; 66:596.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/19/32057/abstract/26\">",
"      Dieterich M, Brandt T. Ocular torsion and tilt of subjective visual vertical are sensitive brainstem signs. Ann Neurol 1993; 33:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/19/32057/abstract/27\">",
"      Zwergal A, Rettinger N, Frenzel C, et al. A bucket of static vestibular function. Neurology 2009; 72:1689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/19/32057/abstract/28\">",
"      Lee H, Lee SY, Lee SR, et al. Ocular tilt reaction and anterior inferior cerebellar artery syndrome. J Neurol Neurosurg Psychiatry 2005; 76:1742.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/19/32057/abstract/29\">",
"      Baier B, Dieterich M. Ocular tilt reaction: a clinical sign of cerebellar infarctions? Neurology 2009; 72:572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/19/32057/abstract/30\">",
"      Finke C, Ploner CJ. Pearls &amp; Oy-sters: Vestibular neuritis or not?: The significance of head tilt in a patient with rotatory vertigo. Neurology 2009; 72:e101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/19/32057/abstract/31\">",
"      Baier B, Bense S, Dieterich M. Are signs of ocular tilt reaction in patients with cerebellar lesions mediated by the dentate nucleus? Brain 2008; 131:1445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/19/32057/abstract/32\">",
"      Halmagyi GM, Cremer PD. Assessment and treatment of dizziness. J Neurol Neurosurg Psychiatry 2000; 68:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/19/32057/abstract/33\">",
"      MacDougall HG, Weber KP, McGarvie LA, et al. The video head impulse test: diagnostic accuracy in peripheral vestibulopathy. Neurology 2009; 73:1134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/19/32057/abstract/34\">",
"      Harvey SA, Wood DJ, Feroah TR. Relationship of the head impulse test and head-shake nystagmus in reference to caloric testing. Am J Otol 1997; 18:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/19/32057/abstract/35\">",
"      Harvey SA, Wood DJ. The oculocephalic response in the evaluation of the dizzy patient. Laryngoscope 1996; 106:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/19/32057/abstract/36\">",
"      Beynon GJ, Jani P, Baguley DM. A clinical evaluation of head impulse testing. Clin Otolaryngol Allied Sci 1998; 23:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/19/32057/abstract/37\">",
"      Jorns-H&auml;derli M, Straumann D, Palla A. Accuracy of the bedside head impulse test in detecting vestibular hypofunction. J Neurol Neurosurg Psychiatry 2007; 78:1113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/19/32057/abstract/38\">",
"      Schubert MC, Tusa RJ, Grine LE, Herdman SJ. Optimizing the sensitivity of the head thrust test for identifying vestibular hypofunction. Phys Ther 2004; 84:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/19/32057/abstract/39\">",
"      Weber KP, Aw ST, Todd MJ, et al. Horizontal head impulse test detects gentamicin vestibulotoxicity. Neurology 2009; 72:1417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/19/32057/abstract/40\">",
"      Newman-Toker DE, Kattah JC, Alvernia JE, Wang DZ. Normal head impulse test differentiates acute cerebellar strokes from vestibular neuritis. Neurology 2008; 70:2378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/19/32057/abstract/41\">",
"      Tusa RJ. Bedside assessment of the dizzy patient. Neurol Clin 2005; 23:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/19/32057/abstract/42\">",
"      Dros J, Maarsingh OR, van der Horst HE, et al. Tests used to evaluate dizziness in primary care. CMAJ 2010; 182:E621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/19/32057/abstract/43\">",
"      Kim HA, Hong JH, Lee H, et al. Otolith dysfunction in vestibular neuritis: recovery pattern and a predictor of symptom recovery. Neurology 2008; 70:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/19/32057/abstract/44\">",
"      Mandal&agrave; M, Nuti D, Broman AT, Zee DS. Effectiveness of careful bedside examination in assessment, diagnosis, and prognosis of vestibular neuritis. Arch Otolaryngol Head Neck Surg 2008; 134:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/19/32057/abstract/45\">",
"      Choi KD, Oh SY, Park SH, et al. Head-shaking nystagmus in lateral medullary infarction: patterns and possible mechanisms. Neurology 2007; 68:1337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/19/32057/abstract/46\">",
"      Choi KD, Kim JS, Kim HJ, et al. Hyperventilation-induced nystagmus in peripheral vestibulopathy and cerebellopontine angle tumor. Neurology 2007; 69:1050.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/19/32057/abstract/47\">",
"      Schwartz NE, Venkat C, Albers GW. Transient isolated vertigo secondary to an acute stroke of the cerebellar nodulus. Arch Neurol 2007; 64:897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/19/32057/abstract/48\">",
"      Becker KJ, Purcell LL, Hacke W, Hanley DF. Vertebrobasilar thrombosis: diagnosis, management, and the use of intra-arterial thrombolytics. Crit Care Med 1996; 24:1729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/19/32057/abstract/49\">",
"      Herr RD, Alvord L, Johnson L, et al. Immediate electronystagmography in the diagnosis of the dizzy patient. Ann Emerg Med 1993; 22:1182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/19/32057/abstract/50\">",
"      Minor LB. Clinical manifestations of superior semicircular canal dehiscence. Laryngoscope 2005; 115:1717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/19/32057/abstract/51\">",
"      Iwasaki S, Smulders YE, Burgess AM, et al. Ocular vestibular evoked myogenic potentials in response to bone-conducted vibration of the midline forehead at Fz. A new indicator of unilateral otolithic loss. Audiol Neurootol 2008; 13:396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/19/32057/abstract/52\">",
"      Johnson EW. Auditory findings in 200 cases of acoustic neuromas. Arch Otolaryngol 1968; 88:598.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/19/32057/abstract/53\">",
"      Harner SG, Laws ER Jr. Clinical findings in patients with acoustic neurinoma. Mayo Clin Proc 1983; 58:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/19/32057/abstract/54\">",
"      Selters WA, Brackmann DE. Acoustic tumor detection with brain stem electric response audiometry. Arch Otolaryngol 1977; 103:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/19/32057/abstract/55\">",
"      Bauch CD, Rose DE, Harner SG. Auditory brain stem response results from 255 patients with suspected retrocochlear involvement. Ear Hear 1982; 3:83.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5094 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.234.146.186-40244E071D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_19_32057=[""].join("\n");
var outline_f31_19_32057=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H30\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      HISTORY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Vertigo",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Nausea and vomiting",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Postural instability",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Time course",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Aggravating and provoking factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Associated symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Prior medical history",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Other symptoms of vestibular dysfunction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Tilt illusion",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Drop attacks",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Spatial disorientation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Oscillopsia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Impaired balance without vertigo",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      EXAMINATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Nystagmus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Gait instability",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Other neurologic signs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Office hearing tests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Dix-Hallpike maneuver",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Other vestibular signs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      DIAGNOSTIC TESTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Magnetic resonance imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Electronystagmography and video nystagmography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Vestibular evoked myogenic potentials",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Audiometry",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Brainstem auditory evoked potentials",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/5094\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/5094|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?40/5/41043\" title=\"figure 1\">",
"      Weber and Rinne tests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?34/32/35330\" title=\"figure 2\">",
"      Dix Hallpike maneuver",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?17/19/17715\" title=\"figure 3\">",
"      Head thrust test",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/5094|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?24/7/24688\" title=\"picture 1\">",
"      Bucket test  to find subjective visual vertical",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/5094|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?24/29/25051\" title=\"table 1\">",
"      Causes of vertigo",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?9/14/9453\" title=\"table 2\">",
"      Causes vertigo Clin Features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?29/33/30235\" title=\"table 3\">",
"      Clinical features of central versus peripheral vertigo",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?13/29/13787\" title=\"table 4\">",
"      Interpreting Weber and Rinne tests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?18/15/18683\" title=\"table 5\">",
"      Dix Hallpike findings in central vs peripheral vertigo",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/43/23223?source=related_link\">",
"      Approach to the patient with dizziness",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/13/19673?source=related_link\">",
"      Benign paroxysmal positional vertigo",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/13/27863?source=related_link\">",
"      Clinical neurophysiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/59/29626?source=related_link\">",
"      Concussion and mild traumatic brain injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/32/39429?source=related_link\">",
"      Evaluation of hearing loss in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/61/32729?source=related_link\">",
"      Meniere disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/46/25320?source=related_link\">",
"      Overview of diplopia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/23/34165?source=related_link\">",
"      Overview of nystagmus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/38/17001?source=related_link\">",
"      Pathophysiology, etiology, and differential diagnosis of vertigo",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?40/31/41460?source=related_link\">",
"      Patient information: Dizziness and vertigo (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?40/59/41905?source=related_link\">",
"      Patient information: Vertigo (a type of dizziness) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/22/39273?source=related_link\">",
"      Posterior circulation cerebrovascular syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/9/28825?source=related_link\">",
"      Stupor and coma in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/30/38377?source=related_link\">",
"      The detailed neurologic examination in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/15/13559?source=related_link\">",
"      Treatment of vertigo",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/15/35062?source=related_link\">",
"      Vestibular neuritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/18/40232?source=related_link\">",
"      Vestibular schwannoma (acoustic neuroma)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/62/10217?source=related_link\">",
"      Wernicke's encephalopathy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_19_32058="Overview of intrauterine contraception";
var content_f31_19_32058=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of intrauterine contraception",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/19/32058/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/19/32058/contributors\">",
"     Gillian Dean, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/19/32058/contributors\">",
"     Alisa B Goldberg, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/19/32058/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/19/32058/contributors\">",
"     Mimi Zieman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/19/32058/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/19/32058/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?31/19/32058/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 6, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intrauterine contraception is one of the safest and most effective methods of contraception available today. It is considered &ldquo;top tier contraception&rdquo; because it ranks alongside implants and sterilization in efficacy and requires minimal user effort. Modern devices for intrauterine contraception are made of plastic and release either copper or a progestin to enhance the contraceptive action of the device.",
"   </p>",
"   <p>",
"    Several terms are used to describe intrauterine contraception, including intrauterine device (IUD) and intrauterine contraceptive (IUC); the progestin-containing device is also referred to as an intrauterine system (IUS). In this topic, we use the term IUD for all types of intrauterine contraception.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1109810\">",
"    <span class=\"h1\">",
"     OVERVIEW OF BENEFITS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intrauterine contraception is highly effective, private, long-acting, and rapidly reversible, with few side effects (",
"    <a class=\"graphic graphic_table graphicRef80860 \" href=\"mobipreview.htm?40/39/41595\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/19/32058/abstract/1\">",
"     1",
"    </a>",
"    ]. It is safe for most women, including teens and nulliparous women; there are few contraindications to its use [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/19/32058/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. It does not interfere with the spontaneity of sex, offers several noncontraceptive health benefits, has high user acceptability and continuation, and can be used by women who want or need to avoid exogenous estrogen. The IUD is among the most cost-effective contraceptive options available. In addition, it represents an effective alternative to surgical sterilization, which many women choose in order to avoid the side effects and frequent attention required by most reversible methods of contraception.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1109837\">",
"    <span class=\"h1\">",
"     PREVALENCE OF IUD USE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The IUD is the most commonly used method of reversible contraception worldwide [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/19/32058/abstract/4\">",
"     4",
"    </a>",
"    ]. Use of IUDs has been increasing in the United States. In 2002, only 2 percent of contraceptive users in the United States chose IUDs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/19/32058/abstract/5\">",
"     5",
"    </a>",
"    ], whereas in 2009, this number had increased to 7.7 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/19/32058/abstract/6\">",
"     6",
"    </a>",
"    ]. However, the United States continues to lag behind other countries in IUD use. By comparison, IUDs are used by over 50 percent of contracepting women in parts of Asia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/19/32058/abstract/7,8\">",
"     7,8",
"    </a>",
"    ] and 6 to 27 percent of female contraceptive users in Europe [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/19/32058/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1109852\">",
"    <span class=\"h2\">",
"     Concerns limiting usage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several factors have limited widespread use of the IUD in the United States, including a history of negative publicity; misinformation about the risks of ectopic pregnancy, infection, and infertility; misconceptions about the mechanism of action of the IUD; lack of clinician training; and fears of litigation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/19/32058/abstract/10\">",
"     10",
"    </a>",
"    ]. In the 1970s, the IUD was used by 10 percent of women in the United States using contraception. When the Dalkon Shield (a common IUD used in that era) was linked to pelvic inflammatory disease, utilization of all IUDs fell and litigation rose [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/19/32058/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One likely explanation for the increase in infectious morbidity associated with IUDs in this period is the construction of the tail. The braided and multifilament tails of the plastic IUDs from this era may have acted like wicks and allowed bacteria to ascend to the upper genital tract. Coupled with the fact that no test had yet been developed to detect asymptomatic Chlamydia infection, many women developed severe pelvic infections.",
"   </p>",
"   <p>",
"    Modern IUDs, which have monofilament tail strings, have not been associated with infections, nor with litigation against health care providers or the companies that manufacture IUDs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/19/32058/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. In 2005, the US Food and Drug Administration approved liberalized package labeling for the copper T380A, removing any proscription against its use in nulliparous women or in those with more than one sexual partner.",
"   </p>",
"   <p>",
"    Actively informing women about benefits and risks of long-acting contraceptives, such as the IUD, appears to improve consideration and acceptance of the method [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/19/32058/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MECHANISM OF ACTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The precise mechanism of the contraceptive action of IUDs is not known; it is likely that several factors are involved (",
"    <a class=\"graphic graphic_table graphicRef61064 \" href=\"mobipreview.htm?2/7/2171\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/19/32058/abstract/15-19\">",
"     15-19",
"    </a>",
"    ]. Pregnancy appears to be prevented by a foreign body effect induced by the plastic or metal frame and by local changes resulting from the effects of locally released medication (copper or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/47/25336?source=see_link\">",
"     levonorgestrel",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    IUDs work primarily by preventing fertilization, and do not act as abortifacients (defined as interruption of an implanted pregnancy) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/19/32058/abstract/20\">",
"     20",
"    </a>",
"    ]. When the uterus is exposed to a foreign body, a sterile inflammatory reaction occurs, which is toxic to sperm and ova and impairs implantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/19/32058/abstract/17,19-22\">",
"     17,19-22",
"    </a>",
"    ]. The production of cytotoxic peptides and activation of enzymes lead to inhibition of sperm motility, reduced sperm capacitation and survival, and sperm phagocytosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/19/32058/abstract/23,24\">",
"     23,24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This primary effect of preventing fertilization is supported by three lines of evidence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/19/32058/abstract/17,19,21,25-28\">",
"     17,19,21,25-28",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sensitive assays for human chorionic gonadotropin (HCG) in IUD users did not detect transient \"chemical\" pregnancies",
"     </li>",
"     <li>",
"      Tubal flushing studies did not find sperm or fertilized ova in the fallopian tubes of IUD users, but commonly found them in noncontraceptors",
"     </li>",
"     <li>",
"      IUD users have lower rates of both intrauterine and tubal pregnancy than women not using contraception",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Additional mechanisms of contraception of medicated IUDs include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The free copper and copper salts released by in utero oxidation of copper-containing IUDs enhance the cytotoxic inflammatory reaction within the endometrium (eg, local prostaglandin production is increased), which is toxic to sperm and ova [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/19/32058/abstract/21,22,29\">",
"       21,22,29",
"      </a>",
"      ]. In vitro, copper interferes with sperm migration, viability, and acrosomal reaction [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/19/32058/abstract/30\">",
"       30",
"      </a>",
"      ]. Postfertilization effects also appear to contribute as a secondary contraceptive mechanism [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/19/32058/abstract/16,30\">",
"       16,30",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The progestin secreted by progestin-releasing IUDs thickens cervical mucus, which creates a barrier to sperm penetration into the upper genital tract [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/19/32058/abstract/31\">",
"       31",
"      </a>",
"      ]. In addition, progestins cause endometrial decidualization and glandular atrophy, which are hostile to implantation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/19/32058/abstract/32\">",
"       32",
"      </a>",
"      ]. Progestins also increase expression of glycodelin A in endometrial glands, which inhibits binding of sperm to the egg [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/19/32058/abstract/33\">",
"       33",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Progestin-releasing IUDs produce serum concentrations of progestin that lead to partial inhibition of ovarian follicular development and ovulation. This is not, however, a major contraceptive mechanism; one study found at least 75 percent of women using a",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/47/25336?source=see_link\">",
"       levonorgestrel",
"      </a>",
"      -releasing IUD had ovulatory cycles [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/19/32058/abstract/34\">",
"       34",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     TYPES OF IUDs",
"    </span>",
"    &nbsp;&mdash;&nbsp;The shapes, components, and construction of intrauterine devices have varied widely over time and across the world (",
"    <a class=\"graphic graphic_picture graphicRef61717 \" href=\"mobipreview.htm?6/21/6487\">",
"     picture 1",
"    </a>",
"    ). The three categories of modern IUDs are:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Copper IUDs",
"     </li>",
"     <li>",
"      Progestin-releasing IUDs",
"     </li>",
"     <li>",
"      Unmedicated (inert) IUDs",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The two types of IUDs currently available in the United States are the copper T380A (TCu380A ParaGard&reg;) and the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/47/25336?source=see_link\">",
"     levonorgestrel",
"    </a>",
"    -releasing IUDs (LNg IUD brand names Mirena and Skyla); additional copper, progestin-releasing, and inert IUDs are available worldwide.",
"   </p>",
"   <p>",
"    Both the LNg IUD and the TCu380A are highly effective forms of reversible contraception (",
"    <a class=\"graphic graphic_table graphicRef80860 \" href=\"mobipreview.htm?40/39/41595\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/19/32058/abstract/25,35\">",
"     25,35",
"    </a>",
"    ], with efficacy comparable to the 1.9 percent 10-year cumulative risk of pregnancy after tubal ligation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/19/32058/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     TCu380A (copper) IUD",
"    </span>",
"    &nbsp;&mdash;&nbsp;The TCu380A (Paragard&reg;) contains a T-shaped polyethylene frame with 380 mm",
"    <sup>",
"     2",
"    </sup>",
"    of exposed surface consisting of fine copper wire wound around a vertical stem and copper collars on each of the horizontal arms. There is a 3 mm ball at the base of the stem to decrease the risk of cervical perforation (",
"    <a class=\"graphic graphic_picture graphicRef56136 \" href=\"mobipreview.htm?8/21/8542\">",
"     picture 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/19/32058/abstract/12\">",
"     12",
"    </a>",
"    ]. A white or clear polyethylene monofilament string is knotted through this ball. The frame contains barium sulfate to make it radiopaque. The device is latex-free and clinically relevant allergy to copper is extremely rare [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/19/32058/abstract/37\">",
"     37",
"    </a>",
"    ]. Serum copper levels are higher in TCu380A users compared with nonusers and above the normal blood copper level range; however, this increase in circulating copper does not have a negative clinical impact [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/19/32058/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23830236\">",
"    <span class=\"h3\">",
"     Duration of use",
"    </span>",
"    &nbsp;&mdash;&nbsp;The TCu380A is approved to remain in place for",
"    <strong>",
"     10 years",
"    </strong>",
"    , but appears to be both safe and highly effective for up to 20 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/19/32058/abstract/35,39\">",
"     35,39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23830229\">",
"    <span class=\"h3\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;With perfect use (in which the user checks the strings regularly to detect expulsion), the probability of pregnancy in the first year is 0.6 percent; with typical use, the first-year pregnancy rate is 0.5 to 0.8 percent (",
"    <a class=\"graphic graphic_table graphicRef80860 \" href=\"mobipreview.htm?40/39/41595\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/19/32058/abstract/20,40\">",
"     20,40",
"    </a>",
"    ]. After prolonged continuous use, the cumulative pregnancy rate is 1.6 percent at seven years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/19/32058/abstract/41\">",
"     41",
"    </a>",
"    ], and 2.2 percent at 8 and 12 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/19/32058/abstract/35\">",
"     35",
"    </a>",
"    ]. Overall, the failure rate is substantially less than one per 100 women per year, except in women under age 25 who experience a slightly higher failure rate, most likely because they are more fertile than older women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/19/32058/abstract/20,40\">",
"     20,40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    IUDs with less than 380 mm",
"    <sup>",
"     2",
"    </sup>",
"    of copper and inert IUDs are less effective than those containing 380 mm",
"    <sup>",
"     2",
"    </sup>",
"    or more of copper [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/19/32058/abstract/42,43\">",
"     42,43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Of note, providers and consumers should be aware that counterfeit IUDs, as well as other drugs, are sometimes sold by on-line pharmacies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Levonorgestrel-releasing IUD",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two doses of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/47/25336?source=see_link\">",
"     levonorgestrel",
"    </a>",
"    -releasing IUDs are available: one contains 52 mg initially released at 20",
"    <span class=\"nowrap\">",
"     mcg/day",
"    </span>",
"    (Mirena&reg;) and the other contains 13.5 mg initially released at 14",
"    <span class=\"nowrap\">",
"     mcg/day",
"    </span>",
"    (Skyla&trade;). &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H97147540\">",
"    <span class=\"h3\">",
"     Levonorgestrel-releasing IUD (LNg 20)",
"    </span>",
"    &nbsp;&mdash;&nbsp;The higher dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/47/25336?source=see_link\">",
"     levonorgestrel",
"    </a>",
"    (LNg20) IUD (",
"    <a class=\"graphic graphic_picture graphicRef81587 \" href=\"mobipreview.htm?19/18/19758\">",
"     picture 3",
"    </a>",
"    ) consists of a T-shaped polyethylene frame with a collar containing 52 mg of levonorgestrel dispersed in polydimethylsiloxane attached to a vertical stem. In vivo, the LNg20 IUD initially releases 20 mcg of levonorgestrel daily, declining to 10 to 14 mcg per day after five years. Like the copper IUD, the stem contains",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/17/12564?source=see_link\">",
"     barium",
"    </a>",
"    sulfate so it can be detected by x-ray, and it does not contain latex.",
"   </p>",
"   <p>",
"    The progestin effect is primarily local [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/19/32058/abstract/44\">",
"     44",
"    </a>",
"    ]. The endometrial concentration of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/47/25336?source=see_link\">",
"     levonorgestrel",
"    </a>",
"    is 1000 times higher than that observed with the levonorgestrel subdermal implant [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/19/32058/abstract/45\">",
"     45",
"    </a>",
"    ]. The plasma concentration of levonorgestrel is far lower than the endometrial concentration and varies among patients. It is 100 to 200",
"    <span class=\"nowrap\">",
"     pg/mL",
"    </span>",
"    within the first few weeks of use, with a gradual decline over time and wide individual variation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/19/32058/abstract/46-48\">",
"     46-48",
"    </a>",
"    ]. This level is half that seen with progestin implants (350",
"    <span class=\"nowrap\">",
"     pg/mL)",
"    </span>",
"    and much less than that associated with progestogen-only pills (1500 to 2000",
"    <span class=\"nowrap\">",
"     pg/mL)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/19/32058/abstract/49,50\">",
"     49,50",
"    </a>",
"    ], but high enough to cause systemic side effects in some users [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/19/32058/abstract/12\">",
"     12",
"    </a>",
"    ]. Serum estradiol levels are not affected [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/19/32058/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The LNg20 IUD is approved for up to",
"    <strong>",
"     five years",
"    </strong>",
"    of use, but appears to be effective for up to seven years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/19/32058/abstract/25\">",
"     25",
"    </a>",
"    ]. With perfect use, the probability of pregnancy in the first year is 0.1 percent; with typical use, the first-year pregnancy rate is 0.1 to 0.2 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/19/32058/abstract/25\">",
"     25",
"    </a>",
"    ]. This is comparable to that with sterilization procedures. With seven years of continuous use, the cumulative pregnancy rate is 1.1 percent (",
"    <a class=\"graphic graphic_table graphicRef80860 \" href=\"mobipreview.htm?40/39/41595\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/19/32058/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9220391\">",
"    <span class=\"h3\">",
"     Levonorgestrel-releasing IUD (LNg14)",
"    </span>",
"    &nbsp;&mdash;&nbsp;A low dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/47/25336?source=see_link\">",
"     levonorgestrel",
"    </a>",
"    -releasing IUD became available in the United States in 2013 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/19/32058/abstract/51\">",
"     51",
"    </a>",
"    ]. It contains 13.5 mg levonorgestrel, which is initially released at 14 mcg day, declining to 5",
"    <span class=\"nowrap\">",
"     mcg/day",
"    </span>",
"    after three years. It is smaller in size than the higher dose levonorgestrel IUD and thus may be easier to insert in nulliparous women.",
"   </p>",
"   <p>",
"    Because of the lower",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/47/25336?source=see_link\">",
"     levonorgestrel",
"    </a>",
"    dose, it is approved for up to",
"    <strong>",
"     three",
"    </strong>",
"    <strong>",
"     years",
"    </strong>",
"    of use (the LNg20 IUD is approved for up to five years) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/19/32058/abstract/52\">",
"     52",
"    </a>",
"    ]. In a phase three trial, the Pearl Index estimate for pregnancy in the first year of use was 0.41 pregnancies per 100 woman years and the cumulative three-year pregnancy rate was 0.9 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/19/32058/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Inert IUDs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although unmedicated IUDs are not approved for use in the United States, providers in this country may encounter these contraceptive devices among patients who have lived abroad. Unmedicated IUDs are composed of inert materials such as stainless steel or plastic. The Lippes Loop, a polyethylene device containing",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/17/12564?source=see_link\">",
"     barium",
"    </a>",
"    sulfate with a single filament tail, is used throughout the world. Flexible stainless steel rings visible on x-ray, but with no string, are widely used in China [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/19/32058/abstract/12,20\">",
"     12,20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An advantage of inert IUDs is that they never need to be replaced. However, many practitioners recommend replacing them with hormone releasing or copper IUDs because medicated IUDs are more effective [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/19/32058/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Frameless IUDs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Frameless IUDs are available in several countries, but not the United States. The GyneFix 330 is made up of several copper cylinders threaded onto a polypropylene suture and without the plastic frame common to other IUDs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/19/32058/abstract/53,54\">",
"     53,54",
"    </a>",
"    ]. The FibroPlant is a frameless levonorgestrel-releasing IUD consisting of a nonresorbable thread attached to a fibrous delivery system that releases 14 or 20 mcg of levonorgestrel per day [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/19/32058/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Early generation frameless devices (before 1996) were associated with a high rate of expulsion in the first year [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/19/32058/abstract/56\">",
"     56",
"    </a>",
"    ], but modifications to the introducer systems that anchor the device to the myometrium appear to have overcome this problem, although data are sparse [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/19/32058/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Advantages of these systems are that they are small, effective, and well tolerated. They are as effective as conventional IUDs and probably more adaptable to variations in the shape of the uterine cavity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/19/32058/abstract/56\">",
"     56",
"    </a>",
"    ]. The major disadvantage of frameless IUDs is that they require additional training to learn the insertion technique, which is different from that for other IUDs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     GENERAL APPROACH TO CHOOSING AN IUD",
"    </span>",
"    &nbsp;&mdash;&nbsp;For women who are appropriate candidates for IUD use, this method is an excellent choice because it is highly effective, private, coitus-independent, long-acting, rapidly reversible, cost-effective, and has few side effects. It offers a nonsurgical, reversible alternative to tubal sterilization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/19/32058/abstract/58\">",
"     58",
"    </a>",
"    ]. Patient satisfaction and continuation rates are high [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/19/32058/abstract/59,60\">",
"     59,60",
"    </a>",
"    ]. As an example, a Finnish study including almost 18,000 women using the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/47/25336?source=see_link\">",
"     levonorgestrel",
"    </a>",
"    IUD reported continuation rates at one, two, three, four, and five years of 93, 87, 81, 75, and 65 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/19/32058/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23833362\">",
"    <span class=\"h2\">",
"     Candidates for intrauterine contraception",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ideal candidates for intrauterine contraception are women who:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Desire one of the most effective methods of contraception;",
"     </li>",
"     <li>",
"      Are at low risk of acquiring sexually transmitted infections, since such infections may require removal of the IUD;",
"     </li>",
"     <li>",
"      Are not planning a pregnancy for at least one year, since attempting pregnancy also requires removal of the IUD;",
"     </li>",
"     <li>",
"      Want to use a reversible contraceptive;",
"     </li>",
"     <li>",
"      Want or need to avoid estrogen-based methods.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Use of the IUD in other populations is also reasonable, and may be indicated because of noncontraceptive benefits.",
"   </p>",
"   <p>",
"    Nulliparous women, women in nonmonogamous relationships, adolescents, and women with a history of pelvic inflammatory disease (PID) or ectopic pregnancy can all safely use the IUD with appropriate counseling (see below). The CuT380A IUD can also be used for emergency contraception and both IUDs can be used by women postpartum and postabortion. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/5/31833?source=see_link\">",
"     \"Emergency contraception\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/8/24713?source=see_link\">",
"     \"Postpartum and postabortion contraception\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23833369\">",
"    <span class=\"h3\">",
"     Contraindications",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are relatively few absolute, evidence-based contraindications to intrauterine contraception [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/19/32058/abstract/61\">",
"     61",
"    </a>",
"    ]. When considering any method, its contraceptive and noncontraceptive benefits must be weighed against the risks, as well as the risks of unintended pregnancy with alternative methods of contraception. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Coexistent chronic medical conditions and personal characteristics'",
"    </a>",
"    below.).",
"   </p>",
"   <p>",
"    The following are the major conditions in which intrauterine contraception is contraindicated:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Severe uterine distortion",
"      </strong>",
"      &mdash; Anatomic abnormalities including bicornuate uterus, cervical stenosis, or fibroids severely distorting the uterine cavity are contraindications to use because of increased difficulty with insertion and increased risk of expulsion when an IUD is placed in a distorted, small, or extremely large uterine cavity [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/19/32058/abstract/62\">",
"       62",
"      </a>",
"      ]. Manufacturers recommend that the uterine cavity sound to between 6 and 9 cm for optimal performance, but this is not based on good evidence. Nondistorting fibroids are not a contraindication to intrauterine contraception [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/19/32058/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Active pelvic infection",
"      </strong>",
"      &mdash; IUD insertion in women with active pelvic infection, including PID, endometritis, mucopurulent cervicitis, and pelvic tuberculosis, is contraindicated because the presence of a foreign body may impede resolution of the infection. The IUD may be inserted in women who are at least three months status post-treatment for PID or puerperal or postabortion sepsis. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?19/27/19898?source=see_link&amp;anchor=H9#H9\">",
"       \"Management of problems related to intrauterine contraception\", section on 'Infection'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      In women treated for gonorrhea or chlamydia who desire an IUD, the World Health Organization (WHO) recommends waiting three months before IUD insertion. However, in selected patients with no evidence of PID and who are believed to be at low risk for subsequent infection, we consider the following approach: retest after at least three weeks to confirm the absence of reinfection and repeat the bimanual examination to ensure the absence of cervical motion tenderness, uterine tenderness or other evidence of upper genital tract infection; the IUD may be inserted at the time of the retest in asymptomatic patients. If the retest returns positive, suitability for continued IUD use should be evaluated. If the woman decides to continue the IUD, she and her partner(s) may be treated without removal of the device.",
"      <br/>",
"      <br/>",
"      In asymptomatic patients with unknown STD status, many clinicians test for gonorrhea or chlamydia at the time of IUD insertion. If the test returns positive, the woman and her partner(s) may be treated without removal of the IUD. We recommend a retest after at least three weeks to confirm the absence of reinfection with management as described above.",
"      <br/>",
"      <br/>",
"      Women at increased risk of acquiring an STD can decrease their risk by using condoms in addition to the IUD. The LNg20 IUD may offer more protection against PID than the TCu380A. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Levonorgestrel-releasing IUD'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <strong>",
"       Known or suspected pregnancy",
"      </strong>",
"      &mdash; IUD insertion during pregnancy can lead to miscarriage and increases the risk of septic abortion.",
"     </li>",
"     <li>",
"      <strong>",
"       Wilson's disease or",
"      </strong>",
"      <strong>",
"       copper",
"      </strong>",
"      <strong>",
"       allergy",
"      </strong>",
"      &mdash; The amount of copper released daily by the TCu380A is less than that consumed in the average diet. Although no adverse event related to copper allergy or Wilson's disease has ever been reported in a woman with a copper IUD, hormone-releasing IUDs are preferred for use in women with these conditions [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/19/32058/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Unexplained abnormal uterine bleeding",
"      </strong>",
"      &mdash; Evaluation of women with abnormal uterine bleeding should precede IUD placement since, after placement, the abnormal bleeding may be erroneously attributed to the IUD rather than the preexisting pathology.",
"     </li>",
"     <li>",
"      <strong>",
"       Other",
"      </strong>",
"      &mdash; Current breast cancer is a contraindication to use of the LNg IUD. However, there is no epidemiological evidence of an increased risk of breast cancer with use of this IUD [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/19/32058/abstract/63\">",
"       63",
"      </a>",
"      ]. The LNg IUD has additional relative contraindications related to specific hormonally sensitive conditions, such as active liver disease (",
"      <a class=\"graphic graphic_table graphicRef60832 \" href=\"mobipreview.htm?33/28/34255\">",
"       table 3",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/24/39306?source=see_link&amp;anchor=H3870962#H3870962\">",
"       \"Overview of contraception\", section on 'World Health Organization tables'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A current history of dysmenorrhea or menorrhagia is a relative contraindication to use of the TCu380A IUD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Copper or levonorgestrel?",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most women can safely use either the copper or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/47/25336?source=see_link\">",
"     levonorgestrel",
"    </a>",
"    (LNg) IUD. When counseling a patient about choice of IUD, it is helpful to know her menstrual history, her medical history, her desire for lighter or less painful menses, and her feelings about amenorrhea, unscheduled bleeding, and spotting.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     When to choose copper",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women who may prefer the copper IUD include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/19/32058/abstract/64\">",
"     64",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Women who want or need to avoid exogenous hormones, such as women with recent breast cancer (within five years);",
"     </li>",
"     <li>",
"      Women who wish to avoid the potential progestin-related side effects of the LNg IUD (amenorrhea, unscheduled bleeding, spotting);",
"     </li>",
"     <li>",
"      Women who desire no or minimal interruption in their endogenous menstrual cycle;",
"     </li>",
"     <li>",
"      Women who need uninterrupted contraception for several years: the TCu380A is approved for twice as many years of use as the LNg20 IUD (10 versus 5 years);",
"     </li>",
"     <li>",
"      Women who need emergency contraception. The TCu380A can be inserted for emergency contraception, and then left in place to provide ongoing contraception.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Women considering the copper IUD should be advised that menses may be heavier, longer, or more uncomfortable, particularly in the first several cycles after insertion; use of nonsteroidal antiinflammatory medications can reduce these symptoms. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/27/19898?source=see_link&amp;anchor=H7#H7\">",
"     \"Management of problems related to intrauterine contraception\", section on 'Pain'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Heavy menses and dysmenorrhea are the most frequent reasons for copper IUD removal in the first year [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/19/32058/abstract/65\">",
"     65",
"    </a>",
"    ]. The frequency of side effects was illustrated in a prospective study of 1962 new copper IUD users in which 38 percent reported more menstrual pain during the first nine weeks of use compared to before IUD use and two-thirds reported increased menstrual blood loss compared to before use; however, the frequency of each side-effect decreased over the first year of use [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/19/32058/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Average monthly menstrual blood loss is increased by up to 55 percent throughout the duration of use; however, most women do not discontinue use for this side effect, and the increased blood loss rarely leads to anemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/19/32058/abstract/67\">",
"     67",
"    </a>",
"    ]. In prospective trials, 2 per 100 users per year discontinued the method due to menorrhagia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/19/32058/abstract/25\">",
"     25",
"    </a>",
"    ], although as many as 9 percent discontinued use in the first year after insertion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/19/32058/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A disadvantage of the copper TCu380A is that it does not provide protection against sexually transmitted diseases (STDs) and, compared with users of the LNg20 IUD, there is a greater risk of PID if a TCu380A user is exposed to sexually transmitted infections [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/19/32058/abstract/69\">",
"     69",
"    </a>",
"    ]. The difference in risk of PID is believed to be due to a progestin-mediated reduction in upper tract infection in LNg20 IUD users rather than an increased risk in copper IUD users.",
"   </p>",
"   <p>",
"    As with hormonal contraceptives, use of copper IUDs has been associated with a decreased risk of endometrial cancer; however, the mechanism for this effect from a nonhormonal contraceptive is unknown [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/19/32058/abstract/70,71\">",
"     70,71",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     When to choose levonorgestrel",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women may prefer the LNg IUD if they want to use a hormonal contraceptive with minimal systemic hormonal effects. Women often choose the LNg20 IUD for its many noncontraceptive health benefits, listed below [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/19/32058/abstract/72,73\">",
"     72,73",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Reduction in dysmenorrhea and menstrual bleeding",
"      </strong>",
"      &mdash; Women with heavy and painful menses should consider the LNg20 IUD over the copper IUD. The LNg20 IUD reduces dysmenorrhea and menstrual blood loss from a variety of causes (",
"      <a class=\"graphic graphic_figure graphicRef53157 \" href=\"mobipreview.htm?6/50/6958\">",
"       figure 1",
"      </a>",
"      ). The reduction in menstrual blood loss occurs both in women with normal coagulation and in those with bleeding diatheses, including anticoagulant therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/19/32058/abstract/74-80\">",
"       74-80",
"      </a>",
"      ]. There is good evidence that the LNg20 IUD is an effective treatment of idiopathic menorrhagia, whereas efficacy in treatment of menorrhagia related to uterine fibroids and adenomyosis is less clear. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?19/41/20122?source=see_link\">",
"       \"Chronic menorrhagia or anovulatory uterine bleeding\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/36/28233?source=see_link\">",
"       \"Treatment of primary dysmenorrhea in adult women\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?18/14/18666?source=see_link\">",
"       \"Overview of treatment of uterine leiomyomas (fibroids)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/35/27191?source=see_link\">",
"       \"Uterine adenomyosis\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      The LNg20 IUD is a good choice for women who desire or are not bothered by amenorrhea, as well as those able to tolerate unscheduled light bleeding or spotting, both of which are common side effects. At 24 months of use, 50 percent of LNg20 IUD users have amenorrhea, 25 percent have oligomenorrhea, and 11 percent have spotting; the remainder report either normal or heavy bleeding [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/19/32058/abstract/81\">",
"       81",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Treatment of endometrial hyperplasia and cancer",
"      </strong>",
"      &mdash; The LNg20 IUD appears to be an effective alternative to oral progestins in the treatment of nonatypical endometrial hyperplasia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/19/32058/abstract/82\">",
"       82",
"      </a>",
"      ]. It may be effective for atypical hyperplasia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/19/32058/abstract/82\">",
"       82",
"      </a>",
"      ] and grade 1 stage I endometrial cancer; further study is needed [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/19/32058/abstract/83\">",
"       83",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/58/26535?source=see_link\">",
"       \"Classification and diagnosis of endometrial hyperplasia\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?18/23/18810?source=see_link\">",
"       \"Endometrial carcinoma: Pretreatment evaluation, staging and surgical treatment\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Endometrial protection",
"      </strong>",
"      &mdash; The LNg20 IUD has been used off-label to prevent development of endometrial hyperplasia in perimenopausal and postmenopausal women using estrogen therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/19/32058/abstract/84-86\">",
"       84-86",
"      </a>",
"      ]. While the TCu380A is generally preferred for women with recent breast cancer, the LNg IUD is an alternative in women being treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"       tamoxifen",
"      </a>",
"      , as it appears to protect the uterus against the endometrial effects of the drug [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/19/32058/abstract/87,88\">",
"       87,88",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/38/41576?source=see_link\">",
"       \"Managing the side effects of tamoxifen\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Treatment of endometriosis",
"      </strong>",
"      &mdash; The LNg20 IUD may decrease pain from endometriosis and delay recurrence of endometriosis after surgical excision. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?14/29/14810?source=see_link&amp;anchor=H9#H9\">",
"       \"Overview of the treatment of endometriosis\", section on 'Progestins'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Protection from pelvic inflammatory disease",
"      </strong>",
"      &mdash; The LNg IUD may decrease the risk of PID, as observed with other progestin-containing contraceptives [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/19/32058/abstract/69,89\">",
"       69,89",
"      </a>",
"      ]. Progestin thickens cervical mucus, thereby possibly providing an enhanced barrier against ascending infection.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The main reasons for LNg IUD discontinuation are changes in bleeding pattern, primarily amenorrhea and unscheduled bleeding and spotting. Other side effects resulting in early discontinuation include hormonal side effects, such as breast tenderness, mood changes, and acne [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/19/32058/abstract/25,59\">",
"     25,59",
"    </a>",
"    ]. These side effects are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/27/19898?source=see_link\">",
"     \"Management of problems related to intrauterine contraception\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Special populations and considerations",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Coexistent chronic medical conditions and personal characteristics",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Centers for Disease Control (CDC) (",
"    <a class=\"graphic graphic_table graphicRef74890 \" href=\"mobipreview.htm?12/13/12506\">",
"     table 4",
"    </a>",
"    ) and the WHO have published eligibility criteria tables for intrauterine contraception by maternal medical condition or personal characteristics (",
"    <a class=\"graphic graphic_table graphicRef82680 \" href=\"mobipreview.htm?20/51/21311\">",
"     table 5",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef65586 \" href=\"mobipreview.htm?39/25/40350\">",
"     table 6",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef62351 \" href=\"mobipreview.htm?36/61/37853\">",
"     table 7",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef61848 \" href=\"mobipreview.htm?1/1/1052\">",
"     table 8",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef60832 \" href=\"mobipreview.htm?33/28/34255\">",
"     table 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef75345 \" href=\"mobipreview.htm?38/20/39245\">",
"     table 9",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef55954 \" href=\"mobipreview.htm?5/40/5774\">",
"     table 10",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef78542 \" href=\"mobipreview.htm?22/49/23324\">",
"     table 11",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef69329 \" href=\"mobipreview.htm?19/34/20013\">",
"     table 12",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef54244 \" href=\"mobipreview.htm?36/54/37741\">",
"     table 13",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef65563 \" href=\"mobipreview.htm?41/14/42220\">",
"     table 14",
"    </a>",
"    ). Some of these issues, and others, are discussed in more detail below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Previous problems with IUD",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women who had problems with a previous IUD, including method failure (ie, pregnancy), expulsion, pain, abnormal bleeding, and cervical or uterine perforation, can still use intrauterine contraception, but they should be informed of the recurrence risk and given other options. Depending on the problem (eg, heavy bleeding with a copper device or intermenstrual bleeding with the LNg device), switching from one type of IUD to another might be useful. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/27/19898?source=see_link\">",
"     \"Management of problems related to intrauterine contraception\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Immunocompromised women",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intrauterine contraception does not enhance the risk of HIV acquisition over that in users of other contraceptives (",
"    <a class=\"graphic graphic_table graphicRef74890 \" href=\"mobipreview.htm?12/13/12506\">",
"     table 4",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef54244 \" href=\"mobipreview.htm?36/54/37741\">",
"     table 13",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/19/32058/abstract/90,91\">",
"     90,91",
"    </a>",
"    ]. Limited data also show no increased risk of PID in HIV-infected IUD users compared with HIV-negative IUD users or HIV-infected women not using an IUD; the lack of increased risk also applies to HIV infected women with low CD4 counts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/19/32058/abstract/92,93\">",
"     92,93",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is no evidence of greater cervical shedding of HIV-1 DNA in HIV-infected IUD users and no increased risk of transmission to an HIV-negative partner [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/19/32058/abstract/94\">",
"     94",
"    </a>",
"    ]. In addition, there are no known drug interactions between IUDs and antiretroviral therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/19/32058/abstract/95\">",
"     95",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Women who are HIV-infected, like other women, need effective long-term contraception. In conjunction with correct and consistent condom use, the IUD may be safely used in women with or at risk for HIV infection (",
"    <a class=\"graphic graphic_table graphicRef75345 \" href=\"mobipreview.htm?38/20/39245\">",
"     table 9",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/19/32058/abstract/94\">",
"     94",
"    </a>",
"    ]. However, for women at risk of HIV infection who are also at risk of acquiring other sexually transmitted diseases (STDs), a progestin contraceptive, including the LNg20 IUD, may be preferable due to protection against ascending infections.",
"   </p>",
"   <p>",
"    There are sparse data on the safety and efficacy of IUD use by women with immunosuppression unrelated to HIV (eg, women undergoing cancer chemotherapy, organ transplant recipients, women receiving immunosuppressive therapy for autoimmune disease). In general, the WHO [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/19/32058/abstract/96\">",
"     96",
"    </a>",
"    ], CDC (",
"    <a class=\"graphic graphic_table graphicRef74890 \" href=\"mobipreview.htm?12/13/12506\">",
"     table 4",
"    </a>",
"    ), and Society of Family Planning (SFP) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/19/32058/abstract/97\">",
"     97",
"    </a>",
"    ] do not consider immunosuppression a contraindication to IUD use, primarily based on safety and efficacy data from HIV-positive women.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Adolescents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Age should not be the primary determinant of acceptable candidacy for intrauterine contraception. Other factors, including parity, pregnancy history, medical history, risk of STDs, and prior contraceptive history should govern the decision to provide intrauterine contraception to a particular adolescent. With adequate counseling regarding anticipated side effects and their management, the IUD can be used safely and effectively in adolescents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/19/32058/abstract/98,99\">",
"     98,99",
"    </a>",
"    ]. In a 2012 Committee Opinion, the American College of Obstetricians and Gynecologists (ACOG) concluded that complications of IUDs are rare and differ little between adolescents and older women, and that IUDs can be inserted without technical difficulty in adolescents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/19/32058/abstract/98\">",
"     98",
"    </a>",
"    ]. However, they recommended screening for gonorrhea and chlamydia before or at the time of insertion. They also noted that the LNg IUD may lower the risk of PID in adolescents. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/13/42201?source=see_link\">",
"     \"Contraception: Overview of issues specific to adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Even though pregnancies, expulsions, and removals for bleeding or pain are more frequent among IUD users under age 20 than in older women, the IUD is still more effective than other forms of reversible contraception in this age group [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/19/32058/abstract/40,65,100,101\">",
"     40,65,100,101",
"    </a>",
"    ]. In general, adolescents have better compliance with long-acting methods than they do with daily-use methods [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/19/32058/abstract/99\">",
"     99",
"    </a>",
"    ], but adolescents are more likely to discontinue any contraceptive compared with older women. Rates of infection in adolescent IUD users are similar to those in adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/19/32058/abstract/101\">",
"     101",
"    </a>",
"    ]. Method failure is higher in young women (under the age of 25) since fertility naturally declines with age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/19/32058/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Nulliparous women",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nulliparous women at low risk of STDs can safely use either the TCu380A or LNg IUD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/19/32058/abstract/102,103\">",
"     102,103",
"    </a>",
"    ]. Both have equivalent efficacy in nulliparous and multiparous women, and infection rates are also similar [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/19/32058/abstract/102-105\">",
"     102-105",
"    </a>",
"    ]. Nulliparous women report high acceptability and continuation rates with both IUDs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/19/32058/abstract/102,106,107\">",
"     102,106,107",
"    </a>",
"    ]. However, copper-based IUDs have been associated with a slightly higher frequency of pain, bleeding, and expulsion in nulliparas than in multiparas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/19/32058/abstract/100,102,108\">",
"     100,102,108",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Restrictive product labeling and misinformation about the health risks of IUDs have limited IUD use in nulliparous women in the United States. In the past, package labels for both IUDs available in the US recommended their use only for women with at least one child. In response to research showing that the IUD is an appropriate option for nulliparous and nulligravid women at low risk for STDs, in 2005, the manufacturers of ParaGard&reg; (TCu380A) gained approval from the FDA to change its labeling to reflect these new data. Mirena&reg; continues to recommend use by women who have had at least one child; however, we do not feel that its use should be restricted to parous women.",
"   </p>",
"   <p>",
"    Most women, including nulliparas, experience a rapid return to fertility after discontinuing intrauterine contraception [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/19/32058/abstract/109,110\">",
"     109,110",
"    </a>",
"    ]. However, misinformation about infection and infertility risk has limited the use of IUDs in the United States, particularly in women who have never been pregnant. IUDs are not associated with a clinically meaningful increase in pelvic infections. In a systematic review of 12 WHO studies including almost 23,000 insertions of modern IUDs and 81 subsequent cases of PID, the risk of pelvic infection was highest in the first 20 days after insertion, but this risk was transitory and small (9.7 cases per 1000 woman-years) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/19/32058/abstract/111\">",
"     111",
"    </a>",
"    ]. After 20 days, the risk returned to the background level of non-IUD users and did not increase with prolonged use. In addition, a large well-designed case-control study of nulligravid women with tubal infertility found that women with infertility due to tubal occlusion were no more likely to have previously used a copper IUD than women with infertility due to other factors or fertile controls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/19/32058/abstract/112\">",
"     112",
"    </a>",
"    ]. Moreover, the LNg20 IUD may protect against PID and subsequent infertility in much the same way as other progestin-containing methods, by thickening the cervical mucus and thinning the endometrium.",
"   </p>",
"   <p>",
"    IUD placement is well-tolerated by most nulliparous women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/19/32058/abstract/113\">",
"     113",
"    </a>",
"    ], although nulliparity has also been found to be a predictor of pain with IUD insertion. In several studies, the degree of pain reported by nulliparas was variable, ranging from the low end of the pain scale to moderate to severe [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/19/32058/abstract/114-116\">",
"     114-116",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/29/34265?source=see_link\">",
"     \"Insertion and removal of an intrauterine contraceptive device\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The WHO concluded that the benefits of IUD use outweigh the potential or known risks in nulliparous women (",
"    <a class=\"graphic graphic_table graphicRef82680 \" href=\"mobipreview.htm?20/51/21311\">",
"     table 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/19/32058/abstract/3\">",
"     3",
"    </a>",
"    ]. The SFP concluded, based on level A evidence, that contemporary IUDs are safe for parous and nulliparous women and do not increase the risk of PID and infertility, that IUDs have similarly low failure rates in parous and nulliparous women, and that IUDs are highly acceptable regardless of parity and are more acceptable than other methods of reversible contraception [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/19/32058/abstract/105\">",
"     105",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Prior ectopic pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The IUD is protective against both intrauterine and extrauterine pregnancies and is an acceptable option for women with a history of a prior ectopic pregnancy or risk factors for ectopic pregnancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/19/32058/abstract/25,28,117-121\">",
"     25,28,117-121",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/15/21752?source=see_link\">",
"     \"Incidence, risk factors, and pathology of ectopic pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Women with a past history of ectopic pregnancy can safely use either the LNg or copper IUD. Women using intrauterine contraception have a lower incidence of ectopic pregnancy than noncontracepting women because the IUD works by preventing fertilization as well as implantation. Women using no contraception are 10 times as likely to develop an ectopic pregnancy as IUD users [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/19/32058/abstract/28\">",
"     28",
"    </a>",
"    ]. However, IUD users are at higher risk of having an ectopic pregnancy if pregnancy occurs (1 in 2 pregnancies for the LNg20 IUD and 1 in 16 pregnancies for the copper IUD versus 1 in 50 pregnancies among noncontraceptors) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/19/32058/abstract/122,123\">",
"     122,123",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/15/21752?source=see_link&amp;anchor=H330799#H330799\">",
"     \"Incidence, risk factors, and pathology of ectopic pregnancy\", section on 'Intrauterine devices'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Women who are postabortion, postpartum, or breastfeeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;IUD insertion can be performed immediately after miscarriage, induced abortion, or delivery. Immediate postabortion insertion increases utilization and decreases the likelihood of repeat induced abortion. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/8/24713?source=see_link\">",
"     \"Postpartum and postabortion contraception\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Use for emergency contraception",
"    </span>",
"    &nbsp;&mdash;&nbsp;The TCu380A IUD placed within 120 hours of unprotected intercourse can be used for emergency contraception. The LNg IUD has not been studied for this indication. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/5/31833?source=see_link&amp;anchor=H9#H9\">",
"     \"Emergency contraception\", section on 'Copper intrauterine contraception'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Valvular heart disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with valvular heart disease can use intrauterine contraception because intrauterine contraception does not increase a woman's risk of bacteremia or pelvic inflammatory disease (",
"    <a class=\"graphic graphic_table graphicRef65586 \" href=\"mobipreview.htm?39/25/40350\">",
"     table 6",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef74890 \" href=\"mobipreview.htm?12/13/12506\">",
"     table 4",
"    </a>",
"    ). The American Heart Association does not recommend endocarditis prophylaxis for IUD insertion in the absence of a pelvic infection. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/29/34265?source=see_link&amp;anchor=H10#H10\">",
"     \"Insertion and removal of an intrauterine contraceptive device\", section on 'SBE prophylaxis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A LNg20 IUD is an option for prevention and non-surgical treatment of menorrhagia in women receiving anticoagulant therapy after cardiac valve replacement. In a randomized trial of women with menorrhagia receiving anticoagulant therapy after cardiac valve replacement, women who received the LNg IUD had significant improvement in hemoglobin and less uterine blood loss [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/19/32058/abstract/76\">",
"     76",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Anticoagulation/bleeding diathesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;As discussed above, the LNg20 IUD is an option for prevention and nonsurgical treatment of menorrhagia in women receiving anticoagulant therapy or who have a bleeding diathesis. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'When to choose levonorgestrel'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    There are few data on the risk of procedural bleeding in these women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/19/32058/abstract/77\">",
"     77",
"    </a>",
"    ]. In small case series of women with inherited bleeding diatheses who received hemostatic cover before insertion, there were no bleeding complications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/19/32058/abstract/124\">",
"     124",
"    </a>",
"    ]. In our experience, bleeding complications are minimal among women who have an IUD inserted while anticoagulated. We prefer to use an atraumatic tenaculum for IUD insertion when possible in anticoagulated women, and in general we do not provide hemostatic cover.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Coexistent gynecologic conditions",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no contraindication to intrauterine contraception in women with anovulation, vaginitis, cervical intraepithelial neoplasia, cervical ectropion, a history of benign ovarian cysts, or prior cesarean delivery. There is no information on use in women with a history of ovarian cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/19/32058/abstract/125\">",
"     125",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1591078998\">",
"    <span class=\"h4\">",
"     Fibroids",
"    </span>",
"    &nbsp;&mdash;&nbsp;The IUD may be used by women with fibroids that do not severely distort the uterine cavity in such a way that insertion is not safely possible (",
"    <a class=\"graphic graphic_table graphicRef60832 \" href=\"mobipreview.htm?33/28/34255\">",
"     table 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef74890 \" href=\"mobipreview.htm?12/13/12506\">",
"     table 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/19/32058/abstract/3,126\">",
"     3,126",
"    </a>",
"    ]. Fibroid and uterine volume, as well as vaginal bleeding, often decline after insertion of the LNg IUS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/19/32058/abstract/127,128\">",
"     127,128",
"    </a>",
"    ]. Women with fibroids may have a higher rate of expulsion than women without fibroids [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/19/32058/abstract/127\">",
"     127",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    After treatment of fibroids by uterine artery embolization, it usually takes the uterus three to six months to reach its new reduced size. As a result, we suggest waiting until there is no evidence of ongoing fibroid necrosis (as evidenced by passage of necrotic tissue or watery discharge), and until the uterus has completed its shrinking process before inserting an IUD after embolization for fibroids.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1591079029\">",
"    <span class=\"h4\">",
"     Other gynecological disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;As discussed above, the LNg20 IUD can reduce symptoms of dysmenorrhea, menorrhagia, and endometriosis, and reduce the risk of endometrial hyperplasia and pelvic inflammatory disease. Hemoglobin levels improve in women with iron deficiency anemia secondary to heavy menstrual bleeding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/19/32058/abstract/129\">",
"     129",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'When to choose levonorgestrel'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Cancer risk reduction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Meta-analyses of case&ndash;control and cohort studies found women who have ever used a copper or LNg IUD had reduced risks of endometrial and cervical cancer compared with nonusers (endometrial cancer: pooled adjusted OR 0.6, 95% CI 0.4&ndash;0.7 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/19/32058/abstract/61\">",
"     61",
"    </a>",
"    ]) (cervical cancer OR 0.55, 95% CI 0.42-0.70 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/19/32058/abstract/130\">",
"     130",
"    </a>",
"    ]).",
"   </p>",
"   <p>",
"    One hypothesis for the decreased risk of cervical cancer is that the device or its string triggers a cellular immune response that prevents persistence of HPV infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/19/32058/abstract/130,131\">",
"     130,131",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The LNg20 IUD provides endometrial protection in women at increased risk. A discussion of the LNg IUD for endometrial protection can be found above. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'When to choose levonorgestrel'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     Menopausal women",
"    </span>",
"    &nbsp;&mdash;&nbsp;A copper IUD inserted for contraception should be removed one year after the last menstrual period (ie, menopause) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/19/32058/abstract/132\">",
"     132",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The LNg20 IUD should also be removed one year after cessation of menses in menopausal women not on estrogen replacement. However, because the LNg20 IUD causes amenorrhea in many women, especially with prolonged use, it may be difficult to determine whether menopause has occurred in the absence of other menopausal symptoms. Therefore, in LNg20 users with a history of more than 12 months amenorrhea, we suggest removal of the device at age 51 to 52 years since the average age of menopause is 51.3 years. The LNg20 IUD system may be left in place in women who elect to use estrogen replacement since it will provide protection from endometrial hyperplasia. This protection extends for at least 10 years after the date of insertion.",
"   </p>",
"   <p>",
"    The management of expired and difficult to remove IUDs is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/27/19898?source=see_link&amp;anchor=H1334751797#H1334751797\">",
"     \"Management of problems related to intrauterine contraception\", section on 'Expired and difficult to remove IUDs'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3355244\">",
"    <span class=\"h3\">",
"     Women at risk for osteoporosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neither the LNg IUD not the TCu380A IUD have an adverse effect on bone mineral density [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/19/32058/abstract/133\">",
"     133",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23997947\">",
"    <span class=\"h3\">",
"     Women undergoing magnetic resonance imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with IUDs can undergo magnetic resonance imaging (MRI) procedures safely. Although copper has slight magnetic susceptibility, the IUD does not move, produce artifacts, or significantly increase in temperature during MRI utilized for medical diagnosis (with equipment set to produce magnetic fields &le;3.0 Tesla units) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/19/32058/abstract/134\">",
"     134",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     COST",
"    </span>",
"    &nbsp;&mdash;&nbsp;The LNg20 IUD is more expensive than the TCu380A IUD. Although the initial cost of an IUD is high, the overall cost decreases with each year of use, making this a highly cost-effective method of contraception over time (as long as 10 years). By five years of use, the IUD is one of the two most cost-effective methods of reversible contraception available; the other is the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/1/35863?source=see_link\">",
"     etonogestrel",
"    </a>",
"    implant [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/19/32058/abstract/135\">",
"     135",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The cost-effectiveness of the IUD is illustrated by the following studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In an analysis from 2003, three years of use of either the copper IUD or the LNg IUD was less expensive than 39 cycles of oral contraceptives [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/19/32058/abstract/136\">",
"       136",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Another cost-effectiveness analysis of methods of female contraception found that any contraceptive method was superior to &ldquo;no method.&rdquo; The three least expensive methods over five years of use were the TCu380A IUD (US$647), vasectomy (US$713) and LNg20 IUD (US$930). Cost effectiveness for these methods became significant after about two years of use [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/19/32058/abstract/137\">",
"       137",
"      </a>",
"      ]. Results were sensitive to the cost of the contraceptive method, the cost of an unintended pregnancy, and plan disenrollment rates.",
"     </li>",
"     <li>",
"      In a third study involving almost 1 million contraceptors, intrauterine contraceptives and the contraceptive implant were the most cost-effective, with cost savings of more than $7.00 for every $1.00 spent in services and supplies [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/19/32058/abstract/138\">",
"       138",
"      </a>",
"      ]. Per $1.00 spent, injectable contraceptives yielded savings of $5.60; oral contraceptives, $4.07; the patch, $2.99; the vaginal ring, $2.55; barrier methods, $1.34; and emergency contraceptives, $1.43.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In 2012, the list price of Mirena&reg; is US$843.60 and the list price of ParaGard&reg; is US$754.00 in the United States.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23834300\">",
"    <span class=\"h2\">",
"     Online purchase",
"    </span>",
"    &nbsp;&mdash;&nbsp;Public health authorities have advised against purchase and use of lower cost IUDs that can be bought online because improper storage of these imported devices, especially during transport, may impact product efficacy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/19/32058/abstract/139\">",
"     139",
"    </a>",
"    ]. Legal problems can also arise since federal and state laws in the US require that these devices be FDA approved and purchased through US-licensed pharmaceutical and medical device suppliers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/19/32058/abstract/140\">",
"     140",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h1\">",
"     SIDE EFFECTS AND COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;(See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/27/19898?source=see_link\">",
"     \"Management of problems related to intrauterine contraception\"",
"    </a>",
"    .).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h1\">",
"     INSERTION AND REMOVAL",
"    </span>",
"    &nbsp;&mdash;&nbsp;(See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/29/34265?source=see_link\">",
"     \"Insertion and removal of an intrauterine contraceptive device\"",
"    </a>",
"    .).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?36/17/37138?source=see_link\">",
"       \"Patient information: Intrauterine devices (IUD) (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?1/22/1378?source=see_link\">",
"       \"Patient information: Long-acting methods of birth control (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?4/16/4355?source=see_link\">",
"       \"Patient information: Long-term methods of birth control (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Modern intrauterine contraception (IUD) is highly effective, safe, cost-effective, long-acting, and rapidly reversible with few side effects. It is a private and convenient method of contraception, does not interfere with the spontaneity of sex, is very acceptable to patients, has superior continuation rates, and offers several noncontraceptive health benefits. (See",
"      <a class=\"local\" href=\"#H1109810\">",
"       'Overview of benefits'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The optimal candidates for intrauterine contraception are women who are at low risk of sexually transmitted infections and who want an effective, low-maintenance, reversible contraceptive for use over an extended period of time. IUDs can be used by nulliparous, nulligravid, and adolescent women. Women who want or need to avoid exogenous estrogen can safely use both forms of intrauterine contraception. There are few absolute contraindications to use; the risks and benefits need to be assessed according to individual patient characteristics. (See",
"      <a class=\"local\" href=\"#H23833362\">",
"       'Candidates for intrauterine contraception'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The copper T380A IUD and the",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/47/25336?source=see_link\">",
"       levonorgestrel",
"      </a>",
"      -releasing IUD are the only IUDs approved by the United States Food and Drug Administration for use in the United States. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Types of IUDs'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The LNg IUD and the TCu380A IUD are two of the three most effective forms of reversible contraception available (the single rod implant is the third method). Method failure rates are comparable to tubal sterilization, thus they should be considered as first-line alternatives to surgical sterilization. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Types of IUDs'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Advantages of the TCu380A IUD include that it can be used in women who want or need to avoid hormonal contraception, it may be left in place for as long as 10 years (versus five years for the LNg20 IUD); it may be used for emergency contraception, and it is the only IUD currently approved for postplacental insertion.",
"      <br/>",
"      <br/>",
"      The major disadvantage of the TCu380A is that menses become heavier (approximately 50 percent increase in blood loss) and sometimes more painful. These symptoms can usually be managed by use of nonsteroidal antiinflammatory drugs during menses. The TCu380A should not be used in women with a history of menorrhagia-induced anemia or dysmenorrhea. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Copper or levonorgestrel?'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Advantages of the LNg20 IUD include a significant reduction in menstrual blood loss and dysmenorrhea. For women with heavy or painful menses, we suggest the LNg20 IUD rather than the TCu380A (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). It is a good choice for women who desire or are not bothered by amenorrhea, as well as those able to tolerate unscheduled light bleeding or spotting, both of which are common side effects.",
"      <br/>",
"      <br/>",
"      The LNg20 IUD has several potential noncontraceptive health benefits: it is an alternative to surgical management of menorrhagia and it is being evaluated for treatment of endometrial hyperplasia, for endometrial protection during estrogen therapy and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"       tamoxifen",
"      </a>",
"      use, and in the management of pain related to endometriosis. In addition, the LNg20 IUD may decrease the risk of pelvic inflammatory disease (PID), similar to other progestin-releasing contraceptives. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Copper or levonorgestrel?'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      IUDs decrease the frequency of both intrauterine and extrauterine pregnancy. (See",
"      <a class=\"local\" href=\"#H1109810\">",
"       'Overview of benefits'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/19/32058/abstract/1\">",
"      Thonneau PF, Almont T, Almont TE. Contraceptive efficacy of intrauterine devices. Am J Obstet Gynecol 2008; 198:248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/19/32058/abstract/2\">",
"      Centers for Disease Control and Prevention (CDC). U S. Medical Eligibility Criteria for Contraceptive Use, 2010. MMWR Recomm Rep 2010; 59:1.",
"     </a>",
"    </li>",
"    <li>",
"     World Health Organization. Medical eligibility criteria for contraceptive use. www.who.int (Accessed on January 19, 2012).",
"    </li>",
"    <li>",
"     Population Reference Bureau. Family Planning Worldwide, 2002 Data Sheet. file://www.prb.org/pdf/FamPlanWorldwide_Eng.pdf. (Accessed on January 18, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/19/32058/abstract/5\">",
"      Mosher WD, Martinez GM, Chandra A, et al. Use of contraception and use of family planning services in the United States: 1982-2002. Adv Data 2004; :1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/19/32058/abstract/6\">",
"      Finer LB, Jerman J, Kavanaugh ML. Changes in use of long-acting contraceptive methods in the United States, 2007-2009. Fertil Steril 2012; 98:893.",
"     </a>",
"    </li>",
"    <li>",
"     United Nations, Department of Economic and Social Affairs, Population Division, World contraceptive use 2005., United Nations, New York (2006) Publication ST/ESA/SER.A/253.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/19/32058/abstract/8\">",
"      d'Arcangues C. Worldwide use of intrauterine devices for contraception. Contraception 2007; 75:S2.",
"     </a>",
"    </li>",
"    <li>",
"     Bayer Schering Pharma, 2006 Pan EU Study on Female Contraceptives, 2007, and Guttmacher Institute tabulations of the 2002 National Survey of Family Growth, 2007 at www.guttmacher.org/pubs/gpr/10/4/gpr100419.html (Accessed July 8, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/19/32058/abstract/10\">",
"      Stanwood NL, Garrett JM, Konrad TR. Obstetrician-gynecologists and the intrauterine device: a survey of attitudes and practice. Obstet Gynecol 2002; 99:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/19/32058/abstract/11\">",
"      Hubacher D. The checkered history and bright future of intrauterine contraception in the United States. Perspect Sex Reprod Health 2002; 34:98.",
"     </a>",
"    </li>",
"    <li>",
"     Speroff, L, Darney, P. A Clinical Guide for Contraception, 3rd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2001.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/19/32058/abstract/13\">",
"      Lee NC, Rubin GL, Ory HW, Burkman RT. Type of intrauterine device and the risk of pelvic inflammatory disease. Obstet Gynecol 1983; 62:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/19/32058/abstract/14\">",
"      Arrowsmith ME, Aicken CR, Saxena S, Majeed A. Strategies for improving the acceptability and acceptance of the copper intrauterine device. Cochrane Database Syst Rev 2012; 3:CD008896.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/19/32058/abstract/15\">",
"      Rivera R, Yacobson I, Grimes D. The mechanism of action of hormonal contraceptives and intrauterine contraceptive devices. Am J Obstet Gynecol 1999; 181:1263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/19/32058/abstract/16\">",
"      Stanford JB, Mikolajczyk RT. Mechanisms of action of intrauterine devices: update and estimation of postfertilization effects. Am J Obstet Gynecol 2002; 187:1699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/19/32058/abstract/17\">",
"      Alvarez F, Brache V, Fernandez E, et al. New insights on the mode of action of intrauterine contraceptive devices in women. Fertil Steril 1988; 49:768.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/19/32058/abstract/18\">",
"      Ortiz ME, Croxatto HB. Copper-T intrauterine device and levonorgestrel intrauterine system: biological bases of their mechanism of action. Contraception 2007; 75:S16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/19/32058/abstract/19\">",
"      El-Habashi M, El-Sahwi S, Gawish S, Osman M. Effect of Lippes loop on sperm recovery from human fallopian tubes. Contraception 1980; 22:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/19/32058/abstract/20\">",
"      Mechanism of action, safety and efficacy of intrauterine devices. Report of a WHO Scientific Group. World Health Organ Tech Rep Ser 1987; 753:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/19/32058/abstract/21\">",
"      Ortiz ME, Croxatto HB, Bardin CW. Mechanisms of action of intrauterine devices. Obstet Gynecol Surv 1996; 51:S42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/19/32058/abstract/22\">",
"      Seleem S, Hills FA, Salem HT, et al. Mechanism of action of the intrauterine contraceptive device: evidence for a specific biochemical deficiency in the endometrium. Hum Reprod 1996; 11:1220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/19/32058/abstract/23\">",
"      Sairolu N. Phagocytosis of spermatozoa in the uterine cavity of woman using intrauterine device. Int J Fertil 1971; 16:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/19/32058/abstract/24\">",
"      Amm&auml;l&auml; M, Nyman T, Strengell L, Rutanen EM. Effect of intrauterine contraceptive devices on cytokine messenger ribonucleic acid expression in the human endometrium. Fertil Steril 1995; 63:773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/19/32058/abstract/25\">",
"      Sivin I, Stern J. Health during prolonged use of levonorgestrel 20 micrograms/d and the copper TCu 380Ag intrauterine contraceptive devices: a multicenter study. International Committee for Contraception Research (ICCR). Fertil Steril 1994; 61:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/19/32058/abstract/26\">",
"      Wilcox AJ, Weinberg CR, Armstrong EG, Canfield RE. Urinary human chorionic gonadotropin among intrauterine device users: detection with a highly specific and sensitive assay. Fertil Steril 1987; 47:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/19/32058/abstract/27\">",
"      Segal SJ, Alvarez-Sanchez F, Adejuwon CA, et al. Absence of chorionic gonadotropin in sera of women who use intrauterine devices. Fertil Steril 1985; 44:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/19/32058/abstract/28\">",
"      Sivin I. Dose- and age-dependent ectopic pregnancy risks with intrauterine contraception. Obstet Gynecol 1991; 78:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/19/32058/abstract/29\">",
"      Patai K, Szilagyi G, Noszal B, Szentmariay I. Local tissue effects of copper-containing intrauterine devices. Fertil Steril 2003; 80:1281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/19/32058/abstract/30\">",
"      Tetrault AM, Richman SM, Fei X, Taylor HS. Decreased endometrial HOXA10 expression associated with use of the copper intrauterine device. Fertil Steril 2009; 92:1820.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/19/32058/abstract/31\">",
"      Lewis RA, Taylor D, Natavio MF, et al. Effects of the levonorgestrel-releasing intrauterine system on cervical mucus quality and sperm penetrability. Contraception 2010; 82:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/19/32058/abstract/32\">",
"      Scommegna A, Pandya GN, Christ M, et al. Intrauterine administration of progesterone by a slow releasing device. Fertil Steril 1970; 21:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/19/32058/abstract/33\">",
"      Mandelin E, Koistinen H, Koistinen R, et al. Levonorgestrel-releasing intrauterine device-wearing women express contraceptive glycodelin A in endometrium during midcycle: another contraceptive mechanism? Hum Reprod 1997; 12:2671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/19/32058/abstract/34\">",
"      Nilsson CG, L&auml;hteenm&auml;ki PL, Luukkainen T. Ovarian function in amenorrheic and menstruating users of a levonorgestrel-releasing intrauterine device. Fertil Steril 1984; 41:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/19/32058/abstract/35\">",
"      Long-term reversible contraception. Twelve years of experience with the TCu380A and TCu220C. Contraception 1997; 56:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/19/32058/abstract/36\">",
"      Peterson HB, Xia Z, Hughes JM, et al. The risk of pregnancy after tubal sterilization: findings from the U.S. Collaborative Review of Sterilization. Am J Obstet Gynecol 1996; 174:1161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/19/32058/abstract/37\">",
"      Hostynek JJ, Maibach HI. Copper hypersensitivity: dermatologic aspects. Dermatol Ther 2004; 17:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/19/32058/abstract/38\">",
"      De la Cruz D, Cruz A, Arteaga M, et al. Blood copper levels in Mexican users of the T380A IUD. Contraception 2005; 72:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/19/32058/abstract/39\">",
"      Sivin I. Utility and drawbacks of continuous use of a copper T IUD for 20 years. Contraception 2007; 75:S70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/19/32058/abstract/40\">",
"      Sivin I, Schmidt F. Effectiveness of IUDs: a review. Contraception 1987; 36:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/19/32058/abstract/41\">",
"      The TCu380A, TCu220C, multiload 250 and Nova T IUDS at 3,5 and 7 years of use--results from three randomized multicentre trials. World Health Organization. Special Programme of Research, Development and Research Training in Human Reproduction: Task Force on the Safety and Efficacy of Fertility Regulating Methods. Contraception 1990; 42:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/19/32058/abstract/42\">",
"      O'Brien PA, Kulier R, Helmerhorst FM, et al. Copper-containing, framed intrauterine devices for contraception: a systematic review of randomized controlled trials. Contraception 2008; 77:318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/19/32058/abstract/43\">",
"      French R, Van Vliet H, Cowan F, et al. Hormonally impregnated intrauterine systems (IUSs) versus other forms of reversible contraceptives as effective methods of preventing pregnancy. Cochrane Database Syst Rev 2004; :CD001776.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/19/32058/abstract/44\">",
"      Xiao BL, Zhou LY, Zhang XL, et al. Pharmacokinetic and pharmacodynamic studies of levonorgestrel-releasing intrauterine device. Contraception 1990; 41:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/19/32058/abstract/45\">",
"      Nilsson CG, Haukkamaa M, Vierola H, Luukkainen T. Tissue concentrations of levonorgestrel in women using a levonorgestrel-releasing IUD. Clin Endocrinol (Oxf) 1982; 17:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/19/32058/abstract/46\">",
"      Nilsson CG, Lahteenmaki PL, Luukkainen T, Robertson DN. Sustained intrauterine release of levonorgestrel over five years. Fertil Steril 1986; 45:805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/19/32058/abstract/47\">",
"      Luukkainen T, L&auml;hteenm&auml;ki P, Toivonen J. Levonorgestrel-releasing intrauterine device. Ann Med 1990; 22:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/19/32058/abstract/48\">",
"      Seeber B, Ziehr SC, Gschliesser A, et al. Quantitative levonorgestrel plasma level measurements in patients with regular and prolonged use of the levonorgestrel-releasing intrauterine system. Contraception 2012; 86:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/19/32058/abstract/49\">",
"      Orme ML, Back DJ, Breckenridge AM. Clinical pharmacokinetics of oral contraceptive steroids. Clin Pharmacokinet 1983; 8:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/19/32058/abstract/50\">",
"      Sivin I, L&auml;hteenm&auml;ki P, Ranta S, et al. Levonorgestrel concentrations during use of levonorgestrel rod (LNG ROD) implants. Contraception 1997; 55:81.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.drugs.com/pro/skyla-iud.html (Accessed on February 21, 2013).",
"    </li>",
"    <li>",
"     file://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails (Accessed on February 21, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/19/32058/abstract/53\">",
"      Van Kets H, Van der Pas H, Thiery M, et al. The GyneFix implant systems for interval, postabortal and postpartum contraception: a significant advance in long-term reversible contraception. International Study Group on Intrauterine Drug Delivery. Eur J Contracept Reprod Health Care 1997; 2:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/19/32058/abstract/54\">",
"      O'Brien PA, Marfleet C. Frameless versus classical intrauterine device for contraception. Cochrane Database Syst Rev 2001; :CD003282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/19/32058/abstract/55\">",
"      Wildemeersch D. New frameless and framed intrauterine devices and systems - an overview. Contraception 2007; 75:S82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/19/32058/abstract/56\">",
"      Meirik O, Rowe PJ, Peregoudov A, et al. The frameless copper IUD (GyneFix) and the TCu380A IUD: results of an 8-year multicenter randomized comparative trial. Contraception 2009; 80:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/19/32058/abstract/57\">",
"      O'Brien PA, Marfleet C. Frameless versus classical intrauterine device for contraception. Cochrane Database Syst Rev 2005; :CD003282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/19/32058/abstract/58\">",
"      Grimes DA, Mishell DR Jr. Intrauterine contraception as an alternative to interval tubal sterilization. Contraception 2008; 77:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/19/32058/abstract/59\">",
"      Backman T, Huhtala S, Blom T, et al. Length of use and symptoms associated with premature removal of the levonorgestrel intrauterine system: a nation-wide study of 17,360 users. BJOG 2000; 107:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/19/32058/abstract/60\">",
"      Jensen JT, Nelson AL, Costales AC. Subject and clinician experience with the levonorgestrel-releasing intrauterine system. Contraception 2008; 77:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/19/32058/abstract/61\">",
"      Nelson AL. Contraindications to IUD and IUS use. Contraception 2007; 75:S76.",
"     </a>",
"    </li>",
"    <li>",
"     Nelson, AL, Hatcher, RA, Zieman, M, et al. Managing Contraception. Tiger, Georgia: Bridging the Gap Foundation, 2000.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/19/32058/abstract/63\">",
"      Dinger J, Bardenheuer K, Minh TD. Levonorgestrel-releasing and copper intrauterine devices and the risk of breast cancer. Contraception 2011; 83:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/19/32058/abstract/64\">",
"      Penney G, Brechin S, de Souza A, et al. FFPRHC Guidance (January 2004). The copper intrauterine device as long-term contraception. J Fam Plann Reprod Health Care 2004; 30:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/19/32058/abstract/65\">",
"      Rivera R, Chen-Mok M, McMullen S. Analysis of client characteristics that may affect early discontinuation of the TCu-380A IUD. Contraception 1999; 60:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/19/32058/abstract/66\">",
"      Hubacher D, Chen PL, Park S. Side effects from the copper IUD: do they decrease over time? Contraception 2009; 79:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/19/32058/abstract/67\">",
"      Milsom I, Andersson K, Jonasson K, et al. The influence of the Gyne-T 380S IUD on menstrual blood loss and iron status. Contraception 1995; 52:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/19/32058/abstract/68\">",
"      Hubacher D, Reyes V, Lillo S, et al. Preventing copper intrauterine device removals due to side effects among first-time users: randomized trial to study the effect of prophylactic ibuprofen. Hum Reprod 2006; 21:1467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/19/32058/abstract/69\">",
"      Toivonen J. Intrauterine contraceptive device and pelvic inflammatory disease. Ann Med 1993; 25:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/19/32058/abstract/70\">",
"      Guleria K, Agarwal N, Mishra K, et al. Evaluation of endometrial steroid receptors and cell mitotic activity in women using copper intrauterine device: Can Cu-T prevent endometrial cancer? J Obstet Gynaecol Res 2004; 30:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/19/32058/abstract/71\">",
"      Curtis KM, Marchbanks PA, Peterson HB. Neoplasia with use of intrauterine devices. Contraception 2007; 75:S60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/19/32058/abstract/72\">",
"      American College of Obstetricians and Gynecologists Committee on Gynecologic Practice. ACOG committee opinion. No. 337: Noncontraceptive uses of the levonorgestrel intrauterine system. Obstet Gynecol 2006; 107:1479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/19/32058/abstract/73\">",
"      Fraser IS. Non-contraceptive health benefits of intrauterine hormonal systems. Contraception 2010; 82:396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/19/32058/abstract/74\">",
"      Kadir RA, Chi C. Levonorgestrel intrauterine system: bleeding disorders and anticoagulant therapy. Contraception 2007; 75:S123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/19/32058/abstract/75\">",
"      Lukes AS, Reardon B, Arepally G. Use of the levonorgestrel-releasing intrauterine system in women with hemostatic disorders. Fertil Steril 2008; 90:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/19/32058/abstract/76\">",
"      Kilic S, Yuksel B, Doganay M, et al. The effect of levonorgestrel-releasing intrauterine device on menorrhagia in women taking anticoagulant medication after cardiac valve replacement. Contraception 2009; 80:152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/19/32058/abstract/77\">",
"      Culwell KR, Curtis KM. Use of contraceptive methods by women with current venous thrombosis on anticoagulant therapy: a systematic review. Contraception 2009; 80:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/19/32058/abstract/78\">",
"      Pisoni CN, Cuadrado MJ, Khamashta MA, Hunt BJ. Treatment of menorrhagia associated with oral anticoagulation: efficacy and safety of the levonorgestrel releasing intrauterine device (Mirena coil). Lupus 2006; 15:877.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/19/32058/abstract/79\">",
"      Kouides PA. Current understanding of von Willebrand's disease in women - some answers, more questions. Haemophilia 2006; 12 Suppl 3:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/19/32058/abstract/80\">",
"      Chi C, Huq FY, Kadir RA. Levonorgestrel-releasing intrauterine system for the management of heavy menstrual bleeding in women with inherited bleeding disorders: long-term follow-up. Contraception 2011; 83:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/19/32058/abstract/81\">",
"      Hidalgo M, Bahamondes L, Perrotti M, et al. Bleeding patterns and clinical performance of the levonorgestrel-releasing intrauterine system (Mirena) up to two years. Contraception 2002; 65:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/19/32058/abstract/82\">",
"      Buttini MJ, Jordan SJ, Webb PM. The effect of the levonorgestrel releasing intrauterine system on endometrial hyperplasia: an Australian study and systematic review. Aust N Z J Obstet Gynaecol 2009; 49:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/19/32058/abstract/83\">",
"      Dhar KK, NeedhiRajan T, Koslowski M, Woolas RP. Is levonorgestrel intrauterine system effective for treatment of early endometrial cancer? Report of four cases and review of the literature. Gynecol Oncol 2005; 97:924.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/19/32058/abstract/84\">",
"      Suvanto-Luukkonen E, Kauppila A. The levonorgestrel intrauterine system in menopausal hormone replacement therapy: five-year experience. Fertil Steril 1999; 72:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/19/32058/abstract/85\">",
"      Varila E, Wahlstr&ouml;m T, Rauramo I. A 5-year follow-up study on the use of a levonorgestrel intrauterine system in women receiving hormone replacement therapy. Fertil Steril 2001; 76:969.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/19/32058/abstract/86\">",
"      Suhonen S, Holmstr&ouml;m T, L&auml;hteenm&auml;ki P. Three-year follow-up of the use of a levonorgestrel-releasing intrauterine system in hormone replacement therapy. Acta Obstet Gynecol Scand 1997; 76:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/19/32058/abstract/87\">",
"      Gardner FJ, Konje JC, Abrams KR, et al. Endometrial protection from tamoxifen-stimulated changes by a levonorgestrel-releasing intrauterine system: a randomised controlled trial. Lancet 2000; 356:1711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/19/32058/abstract/88\">",
"      Gardner FJ, Konje JC, Bell SC, et al. Prevention of tamoxifen induced endometrial polyps using a levonorgestrel releasing intrauterine system long-term follow-up of a randomised control trial. Gynecol Oncol 2009; 114:452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/19/32058/abstract/89\">",
"      Toivonen J, Luukkainen T, Allonen H. Protective effect of intrauterine release of levonorgestrel on pelvic infection: three years' comparative experience of levonorgestrel- and copper-releasing intrauterine devices. Obstet Gynecol 1991; 77:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/19/32058/abstract/90\">",
"      Curtis KM, Chrisman CE, Peterson HB, WHO Programme for Mapping Best Practices in Reproductive Health. Contraception for women in selected circumstances. Obstet Gynecol 2002; 99:1100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/19/32058/abstract/91\">",
"      Stringer EM, Kaseba C, Levy J, et al. A randomized trial of the intrauterine contraceptive device vs hormonal contraception in women who are infected with the human immunodeficiency virus. Am J Obstet Gynecol 2007; 197:144.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/19/32058/abstract/92\">",
"      Browne H, Manipalviratn S, Armstrong A. Using an intrauterine device in immunocompromised women. Obstet Gynecol 2008; 112:667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/19/32058/abstract/93\">",
"      Heikinheimo O, Lehtovirta P, Aho I, et al. The levonorgestrel-releasing intrauterine system in human immunodeficiency virus-infected women: a 5-year follow-up study. Am J Obstet Gynecol 2011; 204:126.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/19/32058/abstract/94\">",
"      Casta&ntilde;o PM. Use of intrauterine devices and systems by HIV-infected women. Contraception 2007; 75:S51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/19/32058/abstract/95\">",
"      Heikinheimo O, Lehtovirta P, Suni J, Paavonen J. The levonorgestrel-releasing intrauterine system (LNG-IUS) in HIV-infected women--effects on bleeding patterns, ovarian function and genital shedding of HIV. Hum Reprod 2006; 21:2857.",
"     </a>",
"    </li>",
"    <li>",
"     WHO Medical eligibility criteria for contraceptive use. Fourth edition, 2009. file://whqlibdoc.who.int/publications/2010/9789241563888_eng.pdf.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/19/32058/abstract/97\">",
"      Patel A, Schwarz EB, Society of Family Planning. Cancer and contraception. Release date May 2012. SFP Guideline #20121. Contraception 2012; 86:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/19/32058/abstract/98\">",
"      Committee on Adolescent Health Care Long-Acting Reversible Contraception Working Group, The American College of Obstetricians and Gynecologists. Committee opinion no. 539: adolescents and long-acting reversible contraception: implants and intrauterine devices. Obstet Gynecol 2012; 120:983.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/19/32058/abstract/99\">",
"      Deans EI, Grimes DA. Intrauterine devices for adolescents: a systematic review. Contraception 2009; 79:418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/19/32058/abstract/100\">",
"      Zhang J, Feldblum PJ, Chi IC, Farr MG. Risk factors for copper T IUD expulsion: an epidemiologic analysis. Contraception 1992; 46:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/19/32058/abstract/101\">",
"      D&iacute;az J, Pinto Neto AM, Bahamondes L, et al. Performance of the copper T 200 in parous adolescents: are copper IUDs suitable for these women? Contraception 1993; 48:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/19/32058/abstract/102\">",
"      Hubacher D. Copper intrauterine device use by nulliparous women: review of side effects. Contraception 2007; 75:S8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/19/32058/abstract/103\">",
"      Prager S, Darney PD. The levonorgestrel intrauterine system in nulliparous women. Contraception 2007; 75:S12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/19/32058/abstract/104\">",
"      Due&ntilde;as JL, Albert A, Carrasco F. Intrauterine contraception in nulligravid vs parous women. Contraception 1996; 53:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/19/32058/abstract/105\">",
"      Lyus R, Lohr P, Prager S, Board of the Society of Family Planning. Use of the Mirena LNG-IUS and Paragard CuT380A intrauterine devices in nulliparous women. Contraception 2010; 81:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/19/32058/abstract/106\">",
"      Suhonen S, Haukkamaa M, Jakobsson T, Rauramo I. Clinical performance of a levonorgestrel-releasing intrauterine system and oral contraceptives in young nulliparous women: a comparative study. Contraception 2004; 69:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/19/32058/abstract/107\">",
"      Wildemeersch D, Janssens D, Vrijens M, Weyers S. Ease of insertion, contraceptive efficacy and safety of new T-shaped levonorgestrel-releasing intrauterine systems. Contraception 2005; 71:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/19/32058/abstract/108\">",
"      Petersen KR, Brooks L, Jacobsen B, Skouby SO. Intrauterine devices in nulliparous women. Adv Contracept 1991; 7:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/19/32058/abstract/109\">",
"      Huggins GR, Cullins VE. Fertility after contraception or abortion. Fertil Steril 1990; 54:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/19/32058/abstract/110\">",
"      Hov GG, Skjeldestad FE, Hilstad T. Use of IUD and subsequent fertility--follow-up after participation in a randomized clinical trial. Contraception 2007; 75:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/19/32058/abstract/111\">",
"      Farley TM, Rosenberg MJ, Rowe PJ, et al. Intrauterine devices and pelvic inflammatory disease: an international perspective. Lancet 1992; 339:785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/19/32058/abstract/112\">",
"      Hubacher D, Lara-Ricalde R, Taylor DJ, et al. Use of copper intrauterine devices and the risk of tubal infertility among nulligravid women. N Engl J Med 2001; 345:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/19/32058/abstract/113\">",
"      Brockmeyer A, Kishen M, Webb A. Experience of IUD/IUS insertions and clinical performance in nulliparous women--a pilot study. Eur J Contracept Reprod Health Care 2008; 13:248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/19/32058/abstract/114\">",
"      S&auml;&auml;v I, Aronsson A, Marions L, et al. Cervical priming with sublingual misoprostol prior to insertion of an intrauterine device in nulliparous women: a randomized controlled trial. Hum Reprod 2007; 22:2647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/19/32058/abstract/115\">",
"      Farmer M, Webb A. Intrauterine device insertion-related complications: can they be predicted? J Fam Plann Reprod Health Care 2003; 29:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/19/32058/abstract/116\">",
"      Hubacher D, Reyes V, Lillo S, et al. Pain from copper intrauterine device insertion: randomized trial of prophylactic ibuprofen. Am J Obstet Gynecol 2006; 195:1272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/19/32058/abstract/117\">",
"      A multinational case-control study of ectopic pregnancy. The World Health Organization's Special Programme of Research, Development and Research Training in Human Reproduction: Task Force on Intrauterine Devices for Fertility Regulation. Clin Reprod Fertil 1985; 3:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/19/32058/abstract/118\">",
"      Marchbanks PA, Annegers JF, Coulam CB, et al. Risk factors for ectopic pregnancy. A population-based study. JAMA 1988; 259:1823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/19/32058/abstract/119\">",
"      Ory HW. Ectopic pregnancy and intrauterine contraceptive devices: new perspectives. The Women's Health Study. Obstet Gynecol 1981; 57:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/19/32058/abstract/120\">",
"      Edelman DA, Porter CW. The intrauterine device and ectopic pregnancy. Contraception 1987; 36:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/19/32058/abstract/121\">",
"      Skjeldestad FE. How effectively do copper intrauterine devices prevent ectopic pregnancy? Acta Obstet Gynecol Scand 1997; 76:684.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/19/32058/abstract/122\">",
"      Furlong LA. Ectopic pregnancy risk when contraception fails. A review. J Reprod Med 2002; 47:881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/19/32058/abstract/123\">",
"      Backman T, Rauramo I, Huhtala S, Koskenvuo M. Pregnancy during the use of levonorgestrel intrauterine system. Am J Obstet Gynecol 2004; 190:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/19/32058/abstract/124\">",
"      Kingman CE, Kadir RA, Lee CA, Economides DL. The use of levonorgestrel-releasing intrauterine system for treatment of menorrhagia in women with inherited bleeding disorders. BJOG 2004; 111:1425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/19/32058/abstract/125\">",
"      Zapata LB, Whiteman MK, Marchbanks PA, Curtis KM. Intrauterine device use among women with ovarian cancer: a systematic review. Contraception 2010; 82:38.",
"     </a>",
"    </li>",
"    <li>",
"     Centers for Disease Control and Prevention. Morbidity and Mortality Weekly Report (MMWR). U.S. Medical Eligibility Criteria for Contraceptive Use, 2010. Adapted from the World Health Organization Medical Eligibility Criteria for Contraceptive Use, 4th edition. Early release - May 28, 2010. file://www.cdc.gov/mmwr/preview/mmwrhtml/rr59e0528a1.htm (Accessed on May 28, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/19/32058/abstract/127\">",
"      Zapata LB, Whiteman MK, Tepper NK, et al. Intrauterine device use among women with uterine fibroids: a systematic review. Contraception 2010; 82:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/19/32058/abstract/128\">",
"      Grigorieva V, Chen-Mok M, Tarasova M, Mikhailov A. Use of a levonorgestrel-releasing intrauterine system to treat bleeding related to uterine leiomyomas. Fertil Steril 2003; 79:1194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/19/32058/abstract/129\">",
"      Xiao B, Wu SC, Chong J, et al. Therapeutic effects of the levonorgestrel-releasing intrauterine system in the treatment of idiopathic menorrhagia. Fertil Steril 2003; 79:963.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/19/32058/abstract/130\">",
"      Castellsagu&eacute; X, D&iacute;az M, Vaccarella S, et al. Intrauterine device use, cervical infection with human papillomavirus, and risk of cervical cancer: a pooled analysis of 26 epidemiological studies. Lancet Oncol 2011; 12:1023.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/19/32058/abstract/131\">",
"      Petry KU. Loops in the natural history of cervical cancer. Lancet Oncol 2011; 12:986.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/19/32058/abstract/132\">",
"      ACOG Committee on Practice Bulletins-Gynecology. ACOG practice bulletin. Clinical management guidelines for obstetrician-gynecologists. Number 59, January 2005. Intrauterine device. Obstet Gynecol 2005; 105:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/19/32058/abstract/133\">",
"      Bahamondes MV, Monteiro I, Castro S, et al. Prospective study of the forearm bone mineral density of long-term users of the levonorgestrel-releasing intrauterine system. Hum Reprod 2010; 25:1158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/19/32058/abstract/134\">",
"      Correia L, Ramos AB, Machado AI, et al. Magnetic resonance imaging and gynecological devices. Contraception 2012; 85:538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/19/32058/abstract/135\">",
"      Chiou CF, Trussell J, Reyes E, et al. Economic analysis of contraceptives for women. Contraception 2003; 68:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/19/32058/abstract/136\">",
"      Weir E, Society of Obstetricians and Gynaecologists of Canada. Preventing pregnancy: a fresh look at the IUD. CMAJ 2003; 169:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/19/32058/abstract/137\">",
"      Trussell J, Lalla AM, Doan QV, et al. Cost effectiveness of contraceptives in the United States. Contraception 2009; 79:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/19/32058/abstract/138\">",
"      Foster DG, Rostovtseva DP, Brindis CD, et al. Cost savings from the provision of specific methods of contraception in a publicly funded program. Am J Public Health 2009; 99:446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/19/32058/abstract/139\">",
"      Nelson AL. Buyer beware. Contraception 2009; 80:495.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.miwww.acog.org/departments/dept_notice.cfm?recno=19&amp;bulletin=4785 file://www.miwww.acog.org/departments/dept_notice.cfm?recno=19&amp;bulletin=4785 (Accessed on July 15, 2010).",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5419 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-110.137.129.113-2110654F66-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_19_32058=[""].join("\n");
var outline_f31_19_32058=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H33\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1109810\">",
"      OVERVIEW OF BENEFITS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1109837\">",
"      PREVALENCE OF IUD USE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1109852\">",
"      Concerns limiting usage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MECHANISM OF ACTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      TYPES OF IUDs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      TCu380A (copper) IUD",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23830236\">",
"      - Duration of use",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23830229\">",
"      - Efficacy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Levonorgestrel-releasing IUD",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H97147540\">",
"      - Levonorgestrel-releasing IUD (LNg 20)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9220391\">",
"      - Levonorgestrel-releasing IUD (LNg14)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Inert IUDs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Frameless IUDs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      GENERAL APPROACH TO CHOOSING AN IUD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23833362\">",
"      Candidates for intrauterine contraception",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23833369\">",
"      - Contraindications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Copper or levonorgestrel?",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - When to choose copper",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - When to choose levonorgestrel",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Special populations and considerations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Coexistent chronic medical conditions and personal characteristics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Previous problems with IUD",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Immunocompromised women",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Adolescents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Nulliparous women",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Prior ectopic pregnancy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Women who are postabortion, postpartum, or breastfeeding",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Use for emergency contraception",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Valvular heart disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Anticoagulation/bleeding diathesis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Coexistent gynecologic conditions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H1591078998\">",
"      Fibroids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H1591079029\">",
"      Other gynecological disorders",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Cancer risk reduction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - Menopausal women",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3355244\">",
"      - Women at risk for osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23997947\">",
"      - Women undergoing magnetic resonance imaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      COST",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23834300\">",
"      Online purchase",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      SIDE EFFECTS AND COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      INSERTION AND REMOVAL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/5419\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/5419|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?6/50/6958\" title=\"figure 1\">",
"      Change hemoglobin with IUD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/5419|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?6/21/6487\" title=\"picture 1\">",
"      IUDs from around the world",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?8/21/8542\" title=\"picture 2\">",
"      Tcu-380A IUD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?19/18/19758\" title=\"picture 3\">",
"      Mirena IUD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/5419|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?40/39/41595\" title=\"table 1\">",
"      IUD failure rates",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?2/7/2171\" title=\"table 2\">",
"      IUD mechanism of action",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?33/28/34255\" title=\"table 3\">",
"      WHO MEC for reproductive tract infections and disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?12/13/12506\" title=\"table 4\">",
"      CDC Medical Eligibility Criteria for Contraceptive Use",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?20/51/21311\" title=\"table 5\">",
"      WHO MEC Personal characteristics and reproductive history",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?39/25/40350\" title=\"table 6\">",
"      WHO criteria for contraceptive use in cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?36/61/37853\" title=\"table 7\">",
"      WHO MEC for neurologic conditions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?1/1/1052\" title=\"table 8\">",
"      WHO MEC for Depressive disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?38/20/39245\" title=\"table 9\">",
"      WHO MEC for women with HIV AIDS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?5/40/5774\" title=\"table 10\">",
"      WHO MEC for gastrointestinal disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?22/49/23324\" title=\"table 11\">",
"      WHO MEC for thalassemia and sickle cell disease and anemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?19/34/20013\" title=\"table 12\">",
"      WHO MEC for patients with endocrine disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?36/54/37741\" title=\"table 13\">",
"      WHO MEC for potential drug interactions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?41/14/42220\" title=\"table 14\">",
"      WHO MEC for patients with systemic lupus erythematosus",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/41/20122?source=related_link\">",
"      Chronic menorrhagia or anovulatory uterine bleeding",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/58/26535?source=related_link\">",
"      Classification and diagnosis of endometrial hyperplasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/13/42201?source=related_link\">",
"      Contraception: Overview of issues specific to adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/5/31833?source=related_link\">",
"      Emergency contraception",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/23/18810?source=related_link\">",
"      Endometrial carcinoma: Pretreatment evaluation, staging and surgical treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/15/21752?source=related_link\">",
"      Incidence, risk factors, and pathology of ectopic pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/29/34265?source=related_link\">",
"      Insertion and removal of an intrauterine contraceptive device",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/27/19898?source=related_link\">",
"      Management of problems related to intrauterine contraception",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/38/41576?source=related_link\">",
"      Managing the side effects of tamoxifen",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/24/39306?source=related_link\">",
"      Overview of contraception",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/29/14810?source=related_link\">",
"      Overview of the treatment of endometriosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/14/18666?source=related_link\">",
"      Overview of treatment of uterine leiomyomas (fibroids)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?36/17/37138?source=related_link\">",
"      Patient information: Intrauterine devices (IUD) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?1/22/1378?source=related_link\">",
"      Patient information: Long-acting methods of birth control (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?4/16/4355?source=related_link\">",
"      Patient information: Long-term methods of birth control (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/8/24713?source=related_link\">",
"      Postpartum and postabortion contraception",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/36/28233?source=related_link\">",
"      Treatment of primary dysmenorrhea in adult women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/35/27191?source=related_link\">",
"      Uterine adenomyosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_19_32059="Diff dx headache with fever";
var content_f31_19_32059=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F80966&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F80966&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Differential diagnosis of headache with fever",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Intracranial infection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Meningitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Bacterial",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Fungal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Viral",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Lymphocytic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Encephalitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Brain abscess",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Subdural empyema",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Systemic infection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bacterial infection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Viral infection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        HIV/AIDS",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Other systemic infection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Other causes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Familial hemiplegic migraine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pituitary apoplexy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rhinosinusitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Subarachnoid hemorrhage",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Malignancy of central nervous system",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_19_32059=[""].join("\n");
var outline_f31_19_32059=null;
var title_f31_19_32060="Cytokine profile in RA";
var content_f31_19_32060=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F82355&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F82355&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Cytokine profile in rheumatoid arthritis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        T cell derived",
"       </td>",
"       <td class=\"subtitle1\">",
"        Macrophage/fibroblast derived",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        IL-1",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        +",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        IL-2",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        IL-3",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        IL-4",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        IL-6",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        +",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        IL-8",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        +",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        IL-10",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        +",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        IL-12",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        +",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        IL-15",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        TNF-alpha",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        +",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        TNF-beta",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        IFN-gamma",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        GM-CSF",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        +",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        G-CSF",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        +",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        M-CSF",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        +",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        TGF-beta",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        +",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        IL-1ra",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        +",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        MCP-1",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        +",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        MIP-1",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        +",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        ENA-78",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        +",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     -: cytokine absent or present in very low concentration; +: cytokine readily detected.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_19_32060=[""].join("\n");
var outline_f31_19_32060=null;
var title_f31_19_32061="Chemo regimens relapsed or refractory AML";
var content_f31_19_32061=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F82823&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F82823&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Chemotherapy regimens for relapsed or refractory acute myeloid leukemia (AML) in adults",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Regimen",
"       </td>",
"       <td class=\"subtitle1\">",
"        Common side effects",
"       </td>",
"       <td class=\"subtitle1\">",
"        Comments",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cytarabine plus daunorubicin",
"       </td>",
"       <td>",
"        Common nonhematologic side effects seen in the majority of patients include stomatitis (mostly mild), alopecia, nausea and vomiting (10 percent severe), and diarrhea (mostly mild). Daunorubicin can be associated with an infusion reaction and cardiac arrhythmias; a flu-like syndrome and rash due to cytarabine may be seen during induction.",
"       </td>",
"       <td>",
"        Re-induction with cytarabine plus daunorubicin will produce a complete remission in approximately 50 percent of patients with a first remission",
"        <strong>",
"         lasting longer than",
"        </strong>",
"        one year",
"        <sup>",
"         [1]",
"        </sup>",
"        .",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        High-dose cytarabine (HiDAC)",
"       </td>",
"       <td>",
"        The most common nonhematologic toxicities are nausea and vomiting, abnormal liver chemistries, diarrhea, conjunctivitis, rash, and cerebellar dysfunction. Toxicity is high in most patients over the age of 60 years.",
"       </td>",
"       <td>",
"        HiDAC may be effective in 35 to 40 percent of patients resistant to conventional dose cytarabine regimens",
"        <sup>",
"         [2]",
"        </sup>",
"        .",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        High-dose cytarabine plus mitoxantrone (HAM)",
"       </td>",
"       <td>",
"        In addition to the side effects described for HiDAC above, nonhematologic toxicities include stomatitis, infections, and neutropenic fever. Infrequent transient, mild cardiac failure and tachyarrhythmias have also been reported.",
"       </td>",
"       <td>",
"        If an anthracycline (eg, daunorubicin) was not used during initial induction, the combination of HiDAC plus the synthetic anthracycline analogue, mitoxantrone, may produce higher response rates than HiDAC alone",
"        <sup>",
"         [3]",
"        </sup>",
"        .",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        High-dose cytarabine plus etoposide",
"       </td>",
"       <td>",
"        In addition to the side effects described for HiDAC above, nonhematologic toxicities include hepatic toxicity, peripheral neuropathy, and anaphylactic-like reaction.",
"       </td>",
"       <td>",
"        HiDAC plus etoposide results in similar response rates as HiDAC alone with a nonsignificant trend towards longer remission duration",
"        <sup>",
"         [4]",
"        </sup>",
"        .",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Mitoxantrone plus etoposide",
"       </td>",
"       <td>",
"        Nonhematologic toxicities include stomatitis, nausea, infections, and neutropenic fever. Infrequent transient, mild cardiac failure and tachyarrhythmias have also been reported.",
"       </td>",
"       <td>",
"        Mitoxantrone and etoposide given together for five days is a commonly used regimen to treat refractory or relapsed AML and has demonstrated complete response rates of approximately 40 percent",
"        <sup>",
"         [5]",
"        </sup>",
"        .",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Mitoxantrone, etoposide, cytarabine (MEC)",
"       </td>",
"       <td>",
"        Side effects are similar to those described for mitoxantrone plus etoposide above, but also include hepatic dysfunction.",
"       </td>",
"       <td>",
"        MEC demonstrates a trend towards higher complete response rates for patients &lt;60 years old and those with unfavorable risk cytogenetics when compared with mitoxantrone plus etoposide alone",
"        <sup>",
"         [6]",
"        </sup>",
"        .",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Fludarabine, cytarabine, plus G-CSF (FLAG)",
"       </td>",
"       <td>",
"        Studies including older adults have reported mild nonhematologic toxicity, most commonly with mucositis.",
"       </td>",
"       <td>",
"        FLAG has reported complete remission rates of 45 to 55 percent in patients with primary refractory or relapsing AML",
"        <sup>",
"         [7]",
"        </sup>",
"        .",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Cladribine, cytarabine, G-CSF (CLAG)",
"       </td>",
"       <td>",
"        Nonhematologic toxicity is generally mild to moderate (grade I/II) and includes fever/infection, mucositis, nausea and vomiting, diarrhea, and alopecia.",
"       </td>",
"       <td>",
"        CLAG results in a complete remission in approximately 50 percent of patients, with a median duration of response of 16 weeks",
"        <sup>",
"         [8]",
"        </sup>",
"        .",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Cyclophosphamide plus high-dose etoposide",
"       </td>",
"       <td>",
"        The most common non-hematologic toxicities include fever/infection, mucositis, hepatic toxicity, and hemorrhagic cystitis.",
"       </td>",
"       <td>",
"        Approximately 42 percent of patients with resistant AML will achieve a complete remission",
"        <sup>",
"         [9]",
"        </sup>",
"        .",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Patients with resistant or relapsed AML should be encouraged to enroll on a clinical trial. While a number of chemotherapy regimens have been used for patients with resistant or relapsed disease, none results in acceptable long term remission rates. Many of these combinations are dose-intensive and cannot easily be applied in older patients. Since these regimens have not been directly compared, a choice is primarily based upon clinical experience and patient co-morbidities. A selection of these regimens is described above. Although response rates are presented for some of these regimens, an individual's chance of responding to a particular regimen is influenced not only by prior exposure to chemotherapy but also by other patient- and leukemia-associated factors. In theory, the preferred regimen to treat relapsed AML would exclude agents at dose levels which the patient has been exposed to recently.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br>",
"      <ol>",
"       <li>",
"        J Clin Oncol 2005; 23:1969.",
"       </li>",
"       <li>",
"        J Clin Oncol 1985; 3:992.",
"       </li>",
"       <li>",
"        Leuk Res 1999; 23:787.",
"       </li>",
"       <li>",
"        Leukemia 1994; 8:1847.",
"       </li>",
"       <li>",
"        J Clin Oncol 1988; 6:213.",
"       </li>",
"       <li>",
"        Leuk Res 2012; 36:394.",
"       </li>",
"       <li>",
"        Br J Haematol 2001; 112:127.",
"       </li>",
"       <li>",
"        Leuk Lymphoma 2000; 39:121.",
"       </li>",
"       <li>",
"        Blood 1990; 76:473.",
"       </li>",
"      </ol>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_19_32061=[""].join("\n");
var outline_f31_19_32061=null;
var title_f31_19_32062="Spirometry technique";
var content_f31_19_32062=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F55460&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F55460&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 474px\">",
"   <div class=\"ttl\">",
"    Technique for performing spirometry",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 454px; height: 350px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Unlike most other medical tests in which the patient remains passive, accurate spirometry requires a coordinated maximum effort. The technician should instruct and encourage the patient to perform the breathing maneuvers in three phases: Phase 1: coach the patient to take as deep a breath as possible; Phase 2: loudly prompt the patient to BLAST out the air into the spirometer; Phase 3: encourage the patient to continue exhaling for several more seconds.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_19_32062=[""].join("\n");
var outline_f31_19_32062=null;
var title_f31_19_32063="Lymphoma bone MRI 2";
var content_f31_19_32063=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F82588&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F82588&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Primary lymphoma of bone",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 377px; height: 362px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This MRI image of the right knee demonstrates a metadiaphyseal lesion of the proximal tibia without extensive cortical destruction (green arrows). The bone lesion was associated with a soft tissue component that was not well-visualized on this image.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Heather Pacholke, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_19_32063=[""].join("\n");
var outline_f31_19_32063=null;
